var title_f17_26_17824="TEP access balloon dissector";
var content_f17_26_17824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    TEP access balloon dissector",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones, DB, Maithel, SK, Schneider, BE. Atlas of minimally invasive surgery. Cin&eacute;-Med, Woodbury, CT 2006. Copyright &copy; 2006 Cin&eacute;-Med, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17824=[""].join("\n");
var outline_f17_26_17824=null;
var title_f17_26_17825="Tendon xanthomata";
var content_f17_26_17825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tendon xanthomata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tendon xanthomata on the dorsum of the hand in a patient with heterozygous familial hypercholesterolemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17825=[""].join("\n");
var outline_f17_26_17825=null;
var title_f17_26_17826="Patient information: Growth hormone treatment (The Basics)";
var content_f17_26_17826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85796\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/36/39503\">",
"         Pituitary gland",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/8/40066\">",
"         Patient information: Acromegaly (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/49/18194\">",
"         Patient information: Carpal tunnel syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/12/3266\">",
"         Patient information: My child is short (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/28/7619\">",
"         Patient information: Pituitary adenoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/42/21155\">",
"         Patient information: Swelling (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/27/43443\">",
"         Patient information: Acromegaly (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/53/32594\">",
"         Patient information: Edema (swelling) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Growth hormone treatment (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H114420229\">",
"      <span class=\"h1\">",
"       What is growth hormone?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Growth hormone is a substance made by a gland located at the base of the brain. This gland is called the pituitary gland (",
"      <a class=\"graphic graphic_figure graphicRef72262 \" href=\"UTD.htm?38/36/39503\">",
"       figure 1",
"      </a>",
"      ). The pituitary gland has different cells in it that make different types of hormones, including growth hormone.",
"     </p>",
"     <p>",
"      Children need growth hormone to grow taller and develop muscles. Adults need growth hormone for their body to work normally.",
"     </p>",
"     <p>",
"      Having too much or too little growth hormone can lead to problems. When people have too little growth hormone, doctors call it a &ldquo;growth hormone deficiency.&rdquo; Doctors can tell if someone has a growth hormone deficiency by doing blood tests.",
"     </p>",
"     <p>",
"      Normally, as adults get older, their pituitary gland makes less growth hormone. This happens in all adults. This is different from a growth hormone deficiency.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114420261\">",
"      <span class=\"h1\">",
"       Who needs treatment with growth hormone?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Children and adults with certain medical conditions need treatment with growth hormone.",
"     </p>",
"     <p>",
"      Doctors can use growth hormone to treat children who have a growth hormone deficiency. They can also use it to treat children who are not growing normally because of certain long-term medical conditions.",
"     </p>",
"     <p>",
"      Doctors can use growth hormone to treat adults with the following conditions:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A growth hormone deficiency &ndash; This is usually caused by a tumor in the pituitary gland. It can also happen as a side effect of treatment for that tumor.",
"       </li>",
"       <li>",
"        Severe muscle loss from an infection called HIV or AIDS",
"       </li>",
"       <li>",
"        A bowel condition called short bowel syndrome",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Growth hormone treatment comes as a shot that people get every day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114420276\">",
"      <span class=\"h1\">",
"       Why might healthy adults want to take growth hormone?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Healthy adults might want to take growth hormone because they might have heard or read about its possible benefits. They might have heard that athletes use it to increase muscle, and that older people use it to feel better and stay younger.",
"     </p>",
"     <p>",
"      Doctors warn that there is no proof that these benefits are real. Although growth hormone might increase muscle and decrease fat, it does not make people stronger or help them perform better in sports. There is also no proof that it helps people stay young.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114420291\">",
"      <span class=\"h1\">",
"       Should healthy adults use growth hormone?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. It is unclear whether taking growth hormone has any health benefits. Adults who want to increase their muscles or decrease their body fat can often do these things by changing their diet and exercising.",
"     </p>",
"     <p>",
"      There are risks associated with taking growth hormone. Growth hormone treatment has side effects that can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Joint pain",
"       </li>",
"       <li>",
"        Increased breast size in men",
"       </li>",
"       <li>",
"        A condition that causes pain and numbness in the fingers and hands, called carpal tunnel syndrome",
"       </li>",
"       <li>",
"        Diabetes (high blood sugar)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Using growth hormone illegally has other risks, too. People who share needles to inject growth hormone can catch infections from others who have used the same needles. Also, growth hormone that is made illegally can have unknown substances in it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114420306\">",
"      <span class=\"h1\">",
"       What about other types of growth hormone products?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some companies sell growth hormone (or growth hormone &ldquo;releaser&rdquo;) pills or sprays. These products have not been proven to work. Also, when growth hormone is taken by mouth, it is changed by digestion and no longer works in the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H114420321\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=see_link\">",
"       Patient information: Pituitary adenoma (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=see_link\">",
"       Patient information: Acromegaly (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=see_link\">",
"       Patient information: Swelling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=see_link\">",
"       Patient information: My child is short (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/49/18194?source=see_link\">",
"       Patient information: Carpal tunnel syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=see_link\">",
"       Patient information: Acromegaly (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=see_link\">",
"       Patient information: Edema (swelling) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/26/17826?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85796 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17826=[""].join("\n");
var outline_f17_26_17826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114420229\">",
"      What is growth hormone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114420261\">",
"      Who needs treatment with growth hormone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114420276\">",
"      Why might healthy adults want to take growth hormone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114420291\">",
"      Should healthy adults use growth hormone?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114420306\">",
"      What about other types of growth hormone products?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114420321\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/36/39503\">",
"      Pituitary gland",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=related_link\">",
"      Patient information: Acromegaly (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=related_link\">",
"      Patient information: Acromegaly (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/49/18194?source=related_link\">",
"      Patient information: Carpal tunnel syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=related_link\">",
"      Patient information: My child is short (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/28/7619?source=related_link\">",
"      Patient information: Pituitary adenoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_26_17827="White plaques of VIN";
var content_f17_26_17827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar intraepithelial neoplasia (VIN)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Raised whitish plaques as a manifestation of VIN.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christine Holschneider, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17827=[""].join("\n");
var outline_f17_26_17827=null;
var title_f17_26_17828="First (thumb) metacarpal fractures";
var content_f17_26_17828=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   First (thumb) metacarpal fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17828/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17828/contributors\">",
"     Josh Bloom, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17828/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17828/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17828/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17828/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/26/17828/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metacarpal fractures are common [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17828/abstract/1\">",
"     1",
"    </a>",
"    ]. They account for 30 to 40 percent of all hand fractures. First metacarpal (thumb) fractures make up almost 25 percent of all metacarpal fractures, placing them second only to fifth metacarpal fractures in terms of frequency. Of these fractures, over 80 percent involve the base of the metacarpal. Thumb fractures occur most often in children (0 to 16 years) and in older patients (&gt;65 years). The thumb provides approximately 40 percent of hand function so metacarpal fractures can have grave consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17828/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review issues related to fractures of the first (thumb) metacarpal. A general overview of metacarpal fractures is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=see_link\">",
"     \"Overview of metacarpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thumb is distinct from the other fingers anatomically and biomechanically. Accordingly, fractures to the thumb are considered separately from other metacarpal fractures. Thumb anatomy is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of thumb metacarpal fractures occur at the base. Fractures of the thumb metacarpal are classified into four patterns (",
"    <a class=\"graphic graphic_figure graphicRef57258 \" href=\"UTD.htm?7/51/7988\">",
"     figure 1",
"    </a>",
"    ). Types I and II are intraarticular fractures and Types III and IV are extraarticular. Discerning whether the articular surface is involved in the fracture is critical as this dictates management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I injury (\"Bennett's fracture\") is a fracture-dislocation of the base of the metacarpal (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72289 \" href=\"UTD.htm?17/30/17888\">",
"       image 2C",
"      </a>",
"      ). In this injury, a proximal metacarpal fragment maintains its ulnar aspect attachment to the trapezium via the volar ligament. The distal aspect of the metacarpal is supinated and dislocated radially by the adductor pollicis. The proximal aspect of this fragment is pulled proximally by the abductor pollicis brevis and abductor pollicis longus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17828/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type II injuries (\"Rolando's fracture\") can be thought of as a comminuted version of a Bennett's fracture, in which the fragments may form a T or Y pattern at the base of the MC (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67033 \" href=\"UTD.htm?42/54/43886\">",
"       image 1",
"      </a>",
"      ). Severe comminution may occur and, in these cases, the classic Y or T pattern is not present. Type II fractures are quite difficult to treat, but fortunately, are a rare type of first metacarpal fracture.",
"     </li>",
"     <li>",
"      Type III fractures are the most common thumb fractures and are extraarticular (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50297 graphicRef63101 \" href=\"UTD.htm?4/2/4129\">",
"       image 2A-B",
"      </a>",
"      ), either transverse or, less commonly, oblique.",
"     </li>",
"     <li>",
"      Type IV fractures are extraarticular pediatric injuries involving the proximal physis and are not addressed in this review.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;First metacarpal fractures typically occur with an axial load to a partially flexed thumb. Fistfights are a frequent culprit in these fractures. First metacarpal fractures can also be seen with hyperabduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperflexion occurring with a fall. If a torsional force is included in the mechanism, the fracture will often be oblique. Intraarticular and extraarticular fractures occur from similar mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAM FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with first metacarpal fractures present with pain, dorsal swelling over the base of the metacarpal and difficulty with range of motion (ROM) at the metacarpophalangeal (MCP) and carpometacarpal (CMC) joints. It is important to distinguish tenderness at the base of the first metacarpal from injury to the scaphoid, trapezium, or distal radius. In addition, if pain, swelling, or ecchymosis occurs more distally at the MCP joint (particularly on the ulnar side), care should be taken to look for a potential injury to the ulnar collateral ligament (\"Game Keeper's Thumb\"). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32068?source=see_link\">",
"     \"Ulnar collateral ligament injury (gamekeeper's or skier's thumb)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three views of the thumb are indicated to assess potential fractures of the thumb metacarpal. In addition to lateral and oblique views, a true AP (Robert's view) should be taken. This view, taken in maximum pronation, provides good visualization of the CMC joint. A true lateral (Bett&rsquo;s view) of a Bennett&rsquo;s fracture dislocation can be obtained with the palm on the cassette, and the hand then pronated 15 to 20 degrees and the tube angled proximally 15 degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17828/abstract/3\">",
"     3",
"    </a>",
"    ]. Close inspection of an apparent extraarticular fracture is required to ensure that no portion of the fracture line involves the joint surface (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72289 graphicRef50297 graphicRef63101 \" href=\"UTD.htm?39/49/40725\">",
"     image 2A-C",
"    </a>",
"    ). An oblique extraarticular injury can be confused with a Bennett's fracture. CT scanning is helpful at times, particularly with regard to potential impaction injury and to define the CMC joint and fracture fragment position in intraarticular injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;All intraarticular first metacarpal fractures warrant referral. Because the integrity of the CMC joint is crucial to hand function, meticulous maintenance of the joint surface is required and most intraarticular fractures require surgical fixation. Less than 1 mm of displacement is desired for optimal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17828/abstract/4\">",
"     4",
"    </a>",
"    ]. Extraarticular fractures, on the other hand, are usually managed without surgical intervention. However, if adequate reduction either cannot be attained by closed manipulation or maintained, referral is indicated. This is particularly important in transverse extraarticular fractures, which often have apex radial angulation. Due to the relatively unstable nature of oblique fractures, patients should be informed about the risk of displacement of these fractures, particularly in those requiring reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splinting is used in the initial immobilization of metacarpal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17828/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. A detailed description of the techniques for applying splints is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"     \"Patient information: Cast and splint care (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intraarticular fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular fractures of the first metacarpal (ie, Type I - Bennett's fracture dislocation and Type II - Rolando's fracture) should be managed initially using a thumb-spica splint (",
"    <a class=\"graphic graphic_picture graphicRef81987 \" href=\"UTD.htm?30/55/31615\">",
"     picture 1",
"    </a>",
"    ) with the interphalangeal (IP) joint free and the wrist in 30 degrees of extension prior to being referred to orthopedics within two to three days. These patients should aggressively ice and elevate the hand and will need adequate analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Extraarticular fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-displaced extraarticular fractures of the first metacarpal should be placed in a short arm thumb-spica splint with the wrist in 30 degrees of extension and the splint extending to the IP joint and followed up in one week (",
"    <a class=\"graphic graphic_picture graphicRef81987 \" href=\"UTD.htm?30/55/31615\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the fracture is oblique or alignment is questionable, the patient should be seen back within three to five days. Up to 30 degrees of residual angularity is tolerated without functional impairment due to the inherent mobility of the thumb. Extraarticular fractures with &gt;30 degrees of angulation require reduction (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Closed reduction'",
"    </a>",
"    below). Definitive treatment for extraarticular fractures is thumb spica cast (with IP joint free) for four to six weeks.",
"   </p>",
"   <p>",
"    Patients should be made aware that significant swelling or overly aggressive icing to this radial side of the thumb can cause a temporary palsy to the superficial radial nerve resulting in numbness over the dorsum of the thumb.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Closed reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;For angulated extraarticular fractures of the first metacarpal, closed reduction is appropriate prior to splinting. Reduction is typically performed by an orthopedic surgeon for thumb metacarpal fractures, however, if reduction is indicated and the treating clinician is comfortable with the procedure, or if there is no referral option available, reduction of extraarticular first metacarpal fractures can be achieved in the following manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anesthesia is generally readily achieved via hematoma block. Placement of a hematoma block for metacarpal fractures is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20565?source=see_link&amp;anchor=H13#H13\">",
"       \"Metacarpal shaft fractures\", section on 'Anesthesia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once adequate anesthesia is confirmed, apply gentle longitudinal traction to the distal fragment while applying pressure over the apex of the fracture and extending the IP joint. Mild pronation of the distal fragment may also help to achieve anatomic alignment. The fracture should then be immobilized with a thumb spica cast and post-reduction x-rays should be obtained to confirm alignment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-displaced fractures and those fractures with good initial reduction should be seen and reimaged in 7 to 10 days. Patients with oblique fractures or questionable reduction require imaging within three to five days. If follow-up films reveal angulation greater than 30 degrees, repeat reduction or referral is indicated.",
"   </p>",
"   <p>",
"    Fractures with stable position should be placed in a short arm thumb spica cast with the wrist in 30 degrees of extension and the IP joint free. Radiographs should be repeated at two-week intervals and immobilization should be continued for a total of four weeks.",
"   </p>",
"   <p>",
"    Following immobilization, active ROM exercise is initiated. Total healing time is six to eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR RETURN TO WORK OR SPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients requiring repetitive gripping at work can expect return to regular duty after they are pain free, the fracture site is nontender, and functional range of motion has been reestablished. If the patient desires return to contact sport, the thumb should be protected in a club-type pad or a firm thumb-spica orthosis for an additional six to eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First (thumb) metacarpal fractures are common and generally involve the base of the metacarpal.",
"     </li>",
"     <li>",
"      The thumb is integral to normal function of the hand. Due to the unique anatomy and biomechanics of the thumb, first metacarpal fractures are described and managed differently than other metacarpal fractures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pertinent anatomy and classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thumb metacarpal fractures are divided into two large groups: intraarticular and extraarticular. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraarticular fractures require orthopedic referral and generally need surgical fixation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extraarticular fractures are typically managed in a closed fashion with thumb-spica immobilization and rarely require surgery. Extraarticular fractures do not require perfect anatomic reduction and can tolerate up to 30 degrees of angulation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oblique extraarticular fractures should be carefully differentiated from Bennett's fractures, are prone to displacement, and need to be observed closely (particularly during the initial two weeks).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374302\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"   <p>",
"    The author and editors would also like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17828/abstract/1\">",
"      Ashkenaze DM, Ruby LK. Metacarpal fractures and dislocations. Orthop Clin North Am 1992; 23:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17828/abstract/2\">",
"      Carlsen BT, Moran SL. Thumb trauma: Bennett fractures, Rolando fractures, and ulnar collateral ligament injuries. J Hand Surg Am 2009; 34:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17828/abstract/3\">",
"      Foster RJ, Hastings H 2nd. Treatment of Bennett, Rolando, and vertical intraarticular trapezial fractures. Clin Orthop Relat Res 1987; :121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17828/abstract/4\">",
"      Soyer AD. Fractures of the base of the first metacarpal: current treatment options. J Am Acad Orthop Surg 1999; 7:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17828/abstract/5\">",
"      Burkhalter WE. Closed treatment of hand fractures. J Hand Surg Am 1989; 14:390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 193 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17828=[""].join("\n");
var outline_f17_26_17828=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAM FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intraarticular fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Extraarticular fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Closed reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS FOR RETURN TO WORK OR SPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H374302\">",
"      ACKNOWLEDGMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/193\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/193|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/54/43886\" title=\"diagnostic image 1\">",
"      Rolando fracture of thumb metacarpal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/26/34222\" title=\"diagnostic image 2A\">",
"      Extraarticular fracture of the first metacarpal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/37/38494\" title=\"diagnostic image 2B\">",
"      Nondisplaced thumb metacarpal fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/30/17888\" title=\"diagnostic image 2C\">",
"      Fracture of thumb metacarpal base Bennetts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/193|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/51/7988\" title=\"figure 1\">",
"      Base of the first metacarpal fracture types",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/193|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/55/31615\" title=\"picture 1\">",
"      Thumb spica splint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20565?source=related_link\">",
"      Metacarpal shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=related_link\">",
"      Overview of metacarpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32068?source=related_link\">",
"      Ulnar collateral ligament injury (gamekeeper's or skier's thumb)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_26_17829="Paclitaxel: Patient drug information";
var content_f17_26_17829=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Paclitaxel: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     see \"Paclitaxel: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33846?source=see_link\">",
"     see \"Paclitaxel: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Paclitaxel&reg;;",
"     </li>",
"     <li>",
"      Paclitaxel for Injection;",
"     </li>",
"     <li>",
"      Paclitaxel Injection USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to paclitaxel or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697314",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever, chills, itching, hives, chest pain or pressure, or shortness of breath when drug is given. Other drugs may be given to avoid these.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       May not be able to get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699037",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as an infusion into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10946 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17829=[""].join("\n");
var outline_f17_26_17829=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205582\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028158\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028160\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028159\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028164\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028165\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028167\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028162\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028169\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=related_link\">",
"      Paclitaxel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33846?source=related_link\">",
"      Paclitaxel: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_26_17830="Melphalan: Patient drug information";
var content_f17_26_17830=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Melphalan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     see \"Melphalan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/41/43670?source=see_link\">",
"     see \"Melphalan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alkeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alkeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to for a few weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700433",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other types of cancer may rarely happen later in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691968",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat multiple myeloma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer of the ovary.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before a bone marrow transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a type of lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3406299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat amyloidosis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702459",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to melphalan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, no period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or mouth sores.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697957",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine to brown or orange.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other kinds of cancer may rarely happen later in life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11391 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17830=[""].join("\n");
var outline_f17_26_17830=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192382\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192383\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018046\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018048\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018047\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018052\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018053\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018055\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018050\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018051\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018056\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018057\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=related_link\">",
"      Melphalan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/41/43670?source=related_link\">",
"      Melphalan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_26_17831="Postmenopausal hormone therapy in the prevention and treatment of osteoporosis";
var content_f17_26_17831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17831/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17831/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17831/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17831/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17831/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17831/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17831/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17831/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/26/17831/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal women have menopause (ovarian failure) at a mean age of 51 years. The resulting lack of estrogen is associated with rapid bone loss due to increased bone resorption and often consequent osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    .) Many women also experience menopausal symptoms, including hot flashes, vaginal dryness, and urinary symptoms, all of which are relieved most effectively by estrogen therapy with or without a progestin.",
"   </p>",
"   <p>",
"    For women with menopausal symptoms, estrogen is often given short-term (six months to five years), with the goal of eventual tapering and discontinuation (unless there is a compelling reason to continue long-term). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to the publication of the Women's Health Initiative, long-term (more than five years) estrogen and combined estrogen-progestin therapy were routinely prescribed for osteoporosis and coronary heart disease (CHD) based upon observational data demonstrating a protective antiresorptive effect of estrogen on bone and a positive effect on the heart.",
"   </p>",
"   <p>",
"    However, currently available data from clinical trials do not confirm that estrogen prevents or delays cardiovascular disease. To the contrary, the Women's Health Initiative (WHI) and other trials suggest that combined estrogen-progestin is not cardioprotective and may slightly increase risk when used for either primary or secondary prevention of CHD. Moreover, combined therapy increases the risk of stroke, venous thromboembolism, and breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/1\">",
"     1",
"    </a>",
"    ], while unopposed estrogen therapy may increase stroke and venous thromboembolism, but not CHD or breast cancer risk. Of note, follow-up analyses suggest that older, but not younger postmenopausal women have excess CHD risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In light of the WHI data and the efficacy of other antiresorptive drugs, including bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , estrogen-progestin therapy should no longer be used solely for the prevention or treatment of osteoporosis. Exceptions include women with persistent menopausal symptoms and those who cannot tolerate the other drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not recommended, this topic will review the efficacy of estrogen therapy on the prevention and treatment of postmenopausal bone loss. The approach to osteoporosis management, the benefits and risks of estrogen therapy, and our current recommendations for estrogen use are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY OF ESTROGEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous randomized, placebo-controlled studies, including the WHI and the Postmenopausal",
"    <span class=\"nowrap\">",
"     Estrogen/Progestin",
"    </span>",
"    Interventions (PEPI) trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/2\">",
"     2",
"    </a>",
"    ], have established that the postmenopausal decrease in bone density is attenuated by estrogen, resulting in a lower risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevention of osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy both prevents osteoporosis and effectively treats it. In one study, as an example, 43 postmenopausal women were randomly assigned to treatment with estrogen, calcium, or placebo for two years, and followed with sequential measurements of bone density by dual photon absorptiometry [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/3\">",
"     3",
"    </a>",
"    ]. Treatment with estrogen prevented bone loss in the forearm and whole body and increased bone density of the spine; it was significantly more effective than calcium or placebo.",
"   </p>",
"   <p>",
"    The results were similar in a placebo-controlled study of 120 postmenopausal women with",
"    <strong>",
"     low bone density",
"    </strong>",
"    who were randomly assigned to treatment with exercise plus either placebo, calcium, or estrogen; these women were followed with sequential measurements of forearm bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/4\">",
"     4",
"    </a>",
"    ]. Although calcium supplementation reduced bone loss at the distal forearm compared with placebo, treatment with estrogen was much more effective in preventing loss of bone density in the proximal, middle, and distal forearm than were the other treatments (",
"    <a class=\"graphic graphic_figure graphicRef62388 \" href=\"UTD.htm?39/13/40157\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fracture risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with bisphosphonate and selective estrogen receptor modulator (SERM) effects on fracture reduction, estrogen therapy-related fracture data has previously been limited. However, in the WHI trial, both unopposed estrogen and combined estrogen-progestin treatment reduced fracture risk. In this study, hip fracture was a secondary outcome, and women were not selected based upon osteoporosis history or risk factors. While bone mineral density was not measured, estrogen-progestin therapy was associated with significant reductions in [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hip fracture (hazard ratio [HR] 0.7, unadjusted 95% CI 0.4-1.0; five fewer hip fractures per 10,000 person-years) (",
"      <a class=\"graphic graphic_figure graphicRef55425 \" href=\"UTD.htm?15/44/16077\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vertebral and other osteoporotic fractures (HR 0.7, unadjusted 95% CI 0.4-1.0; and HR 0.8, 95% CI 0.7-0.9, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar risk reductions were seen in the unopposed estrogen arm of the WHI trial for hip fracture (HR 0.61, 95% CI 0.41-0.91) and vertebral fracture (HR 0.62, 95% CI 0.42-0.93) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/8\">",
"     8",
"    </a>",
"    ]. Other results of the trial are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the WHI, bone mineral density was not a criterion for randomization. Thus, the results are not conclusive because the bone density in the two groups may have been different at baseline. However, most would agree that the WHI provides the best evidence to date that estrogen reduces fracture risk.",
"   </p>",
"   <p>",
"    All types of postmenopausal hormone therapy appear to confer benefit. In a prospective, cohort study of over one million women (the Million Women Study), current users of postmenopausal hormone therapy had a significantly lower risk of any fracture than nonusers (RR 0.62, 95% CI 0.58-0.66) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/9\">",
"     9",
"    </a>",
"    ]. The protective effect was seen for all types of postmenopausal hormone therapy (unopposed estrogen, combined estrogen-progestin, different estrogen and progestin formulations, different routes of administration [oral versus transdermal], and different patterns of administration [cyclic versus continuous]).",
"   </p>",
"   <p>",
"    Concomitant administration of a progestin to prevent endometrial hyperplasia does not interfere with the beneficial effect of estrogen on bone, whether given as cyclic or continuous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Current versus past therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximum protection of bone mass appears to occur when estrogen therapy is begun soon after menopause and then continued indefinitely. As an example, cross-sectional data from the Rancho Bernardo study found that women who had taken estrogen in the past and then discontinued it had slightly higher bone density than women who had never taken estrogen, but their bone density was substantially lower than women currently taking estrogen (",
"    <a class=\"graphic graphic_figure graphicRef51367 \" href=\"UTD.htm?5/59/6079\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/11\">",
"     11",
"    </a>",
"    ]. Among the latter women, the effect of estrogen was almost as good (and not statistically different) when estrogen was started at age 60 years, compared with beginning therapy at menopause. Other studies have noted similar findings: higher bone mass in women currently taking estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/12\">",
"     12",
"    </a>",
"    ] and in those treated long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limited efficacy of past estrogen therapy may reflect \"catch-up\" bone loss, although data have been conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study in 43 postmenopausal women found that those not treated with estrogen after oophorectomy initially lost bone at a rate of 2.6 percent per year, which later fell to 0.8 percent per year (",
"      <a class=\"graphic graphic_figure graphicRef51608 \" href=\"UTD.htm?13/33/13854\">",
"       figure 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/16\">",
"       16",
"      </a>",
"      ]. Those treated with estrogen for four years lost no bone, but after it was discontinued they lost bone at a rate of 2.5 percent per year for the next four years. There was no significant difference in bone loss between the two groups at eight years.",
"     </li>",
"     <li>",
"      In one study of postmenopausal women post-hysterectomy, the women were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      , estrogen, combination therapy, or placebo for two years, followed by further randomization to continued drug therapy or placebo in year three. Bone density decreased in year three after stopping estrogen (-4.5, 1.8, and 2.4 percent in the spine, total hip, and femoral neck, respectively), but not after stopping alendronate or combined alendronate-estrogen treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in the much larger PEPI trial, postmenopausal women who discontinued estrogen did not lose bone at an unusually fast rate. In this study of 495 women who had measurements of bone mineral density for an average of three years during and four years after the trial, annual rates of bone mineral density loss in the women who took estrogen and then stopped it and those who never took estrogen were the same (approximately 1 percent per year) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, data on accelerated bone loss after stopping estrogen therapy are inconsistent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment of established osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although estrogen therapy is FDA approved for prevention but not treatment of osteoporosis, data suggest that estrogen is effective in postmenopausal women with established osteoporosis and vertebral fractures. In one study, 75 such women were randomly assigned to treatment with transdermal estradiol or placebo; calcium supplements were given to both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/20\">",
"     20",
"    </a>",
"    ]. Estrogen was associated with an increase in bone density in the spine and proximal femur, and no change in bone density in the mid-radius. It also lowered the risk of vertebral fractures by more than 50 percent (23 versus 58 fractures per 100 patient-years).",
"   </p>",
"   <p>",
"    Estrogen appears to be effective even when started after age 75 years. As an example, in 67 frail elderly women (over age 75 years), administration of estrogen for nine months increased bone density at the lumbar spine and hip as compared with placebo (4.1 versus 0.4 percent in the spine; 1.7 versus -0.1 percent in the hip) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Low-dose estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of estrogen required to prevent bone loss had been thought to be 0.625 mg of conjugated estrogens or its equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .) However, among postmenopausal women not taking estrogen, those with low (but detectable) serum estradiol concentrations have higher bone density than those with undetectable concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon this observation, lower doses of estrogen have been explored as a strategy to prevent bone loss while minimizing side effects and breast cancer risk. Subsequent studies using DXA for measurement of axial bone density suggest that low doses of estrogen have a protective effect on bone in postmenopausal women, but not quite as much as a standard dose of conjugated estrogens (0.625",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p>",
"    The best data come from a placebo-controlled trial that compared low-dose conjugated estrogens (0.3 or 0.45",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to standard dose therapy (0.625 mg), with or without progestin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    1.5 or 2.5",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    for two years in 822 healthy postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/26\">",
"     26",
"    </a>",
"    ]. Spine and hip bone mineral density increased in a dose-dependent fashion in all hormone treatment groups, but not the placebo group.",
"   </p>",
"   <p>",
"    In another study, 406 recently postmenopausal women were randomly assigned to unopposed esterified estrogen at one of three doses (0.3, 0.625, and 1.25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/27\">",
"     27",
"    </a>",
"    ]. All three doses prevented bone loss, while endometrial hyperplasia occurred only at the two higher doses (",
"    <a class=\"graphic graphic_figure graphicRef50951 \" href=\"UTD.htm?28/28/29134\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is evidence that even ultra-low doses of estrogen (roughly equivalent to conjugated estrogens 0.15",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    provide some protection against bone loss. A",
"    <span class=\"nowrap\">",
"     0.014mg/day",
"    </span>",
"    transdermal estradiol patch and oral estradiol (0.25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    both appear to prevent bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, almost all studies suggest that lower doses of estrogen prevent bone loss, particularly when adequate vitamin D and calcium intake are provided. However, most experts no longer recommend estrogen as first-line therapy for prevention or treatment of osteoporosis, given the results of the WHI. For women using HT for symptomatic relief, the lowest dose for the shortest duration should be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Estrogen versus bisphosphonate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    was similar in efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    therapy for preventing bone loss in one study of women ages 45 to 59 (",
"    <a class=\"graphic graphic_figure graphicRef65252 \" href=\"UTD.htm?15/0/15375\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/30\">",
"     30",
"    </a>",
"    ], and in a study of elderly women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/31\">",
"     31",
"    </a>",
"    ], while alendronate was superior to combination hormone replacement in one study of older postmenopausal women (ages 65 to 90 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/32\">",
"     32",
"    </a>",
"    ]. Bone loss may be greater after stopping estrogen than alendronate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Current versus past therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Combination therapy (estrogen plus bisphosphonate) has been more effective than either agent alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/29,32\">",
"     29,32",
"    </a>",
"    ] in some [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/29,32\">",
"     29,32",
"    </a>",
"    ], but not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/31\">",
"     31",
"    </a>",
"    ]. However, because combination therapy profoundly suppresses bone turnover, we hesitate to give this combination because of the potential for oversuppressing bone turnover, which could increase fracture risk from adynamic or \"frozen\" bone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGESTIN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animals, progesterone may have effects on bone that are independent of those related to estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/33\">",
"     33",
"    </a>",
"    ]. In humans, progesterone inhibits bone resorption and has some beneficial effects on bone density when given to estrogen-deficient women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, the beneficial effect of progesterone on bone mineral density is small compared with that of estrogen. As an example, in one study in postmenopausal women who took either conjugated estrogens (0.625 mg per day), high doses of medroxyprogesterone (20 mg per day), or placebo, spine bone mineral density fell 7 percent in those treated with placebo, but fell only 5 percent in women receiving medroxyprogesterone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/10\">",
"     10",
"    </a>",
"    ]. On the other hand, bone mineral density increased by 2 percent in women taking conjugated estrogens.",
"   </p>",
"   <p>",
"    Combined estrogen-progestin therapy does not increase the efficacy of estrogen alone on bone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. This issue was best addressed in the PEPI trial in which 875 women were randomly assigned to placebo or one of four treatment arms consisting of conjugated estrogens (0.625",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    alone or with cyclic or continuous medroxyprogesterone or cyclic micronized progesterone (200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 12 days per month) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/2\">",
"     2",
"    </a>",
"    ]. At three years, bone density increased similarly in all treatment groups by 3.5 to 5.0 percent at the spine and 1.7 percent at the hip; in contrast, bone density fell at these sites by 1.8 and 1.7 percent, respectively, in the placebo group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although estrogen is an option for the prevention of osteoporosis in perimenopausal women, we no longer consider it a first-line therapy, since data from the WHI suggest that estrogen-progestin therapy reduces fracture risk at a cost of increases in the incidence of breast cancer, coronary heart disease, stroke, and venous thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/1\">",
"     1",
"    </a>",
"    ], or in the case of unopposed estrogen, an increase in stroke and thromboembolism risk (but not CHD or breast cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17831/abstract/8\">",
"     8",
"    </a>",
"    ]. As a result, we recommend bisphosphonates or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    as first-line drugs for prevention and bisphosphonates for treatment of established osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/1\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/2\">",
"      Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996; 276:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/3\">",
"      Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med 1987; 316:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/4\">",
"      Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991; 325:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/5\">",
"      Aloia JF, Vaswani A, Yeh JK, et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994; 120:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/6\">",
"      Munk-Jensen N, Pors Nielsen S, Obel EB, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. Br Med J (Clin Res Ed) 1988; 296:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/7\">",
"      Field CS, Ory SJ, Wahner HW, et al. Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993; 168:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/8\">",
"      Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/9\">",
"      Banks E, Beral V, Reeves G, et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 2004; 291:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/10\">",
"      Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991; 90:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/11\">",
"      Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997; 277:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/12\">",
"      Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/13\">",
"      Cauley JA, Zmuda JM, Ensrud KE, et al. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001; 86:5700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/14\">",
"      Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/15\">",
"      Micha&euml;lsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998; 316:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/16\">",
"      Lindsay R, Hart DM, MacLean A, et al. Bone response to termination of oestrogen treatment. Lancet 1978; 1:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/17\">",
"      Christiansen C, Christensen MS, Transb&oslash;l I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/18\">",
"      Greendale GA, Espeland M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 2002; 162:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/19\">",
"      Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/20\">",
"      Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/21\">",
"      Villareal DT, Binder EF, Williams DB, et al. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA 2001; 286:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/22\">",
"      Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/23\">",
"      Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/24\">",
"      Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996; 276:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/25\">",
"      Ettinger B, Pressman A, Sklarin P, et al. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 1998; 83:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/26\">",
"      Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/27\">",
"      Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997; 157:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/28\">",
"      Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/29\">",
"      Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998; 104:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/30\">",
"      Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/31\">",
"      Evi&ouml; S, Tiitinen A, Laitinen K, et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004; 89:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/32\">",
"      Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003; 289:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/33\">",
"      Prior JC. Progesterone as a bone-trophic hormone. Endocr Rev 1990; 11:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/34\">",
"      Horowitz M, Wishart J, Need AG, et al. Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density. Arch Intern Med 1987; 147:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17831/abstract/35\">",
"      Abdalla HI, Hart DM, Lindsay R, et al. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985; 66:789.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7428 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-201.248.109.99-2F11E81C67-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17831=[""].join("\n");
var outline_f17_26_17831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY OF ESTROGEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fracture risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Current versus past therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment of established osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Low-dose estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Estrogen versus bisphosphonate therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGESTIN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7428\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7428|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/13/40157\" title=\"figure 1\">",
"      Calcium versus estrogen on bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/44/16077\" title=\"figure 2\">",
"      HRT and hip fracture WHI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/59/6079\" title=\"figure 3\">",
"      Current ERT and bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/33/13854\" title=\"figure 4\">",
"      Reversible benefit ERT on BMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/28/29134\" title=\"figure 5\">",
"      Low dose E and BMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/0/15375\" title=\"figure 6\">",
"      Alendronate versus ERT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_26_17832="Abnormalities of coagulation and platelet function in preeclampsia";
var content_f17_26_17832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abnormalities of coagulation and platelet function in preeclampsia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17832/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17832/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17832/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17832/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17832/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17832/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17832/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/26/17832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a common complication of pregnancy, occurring with a frequency of 10 to 15 percent. Its development is due to a number of different and distinct etiological and pathophysiological mechanisms, many of which are poorly understood. Preeclampsia complicates about 5 to 10 percent of hypertensive pregnancies and remains a major cause of maternal and neonatal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal pregnancy is associated with a transient hypercoagulable state, which most likely evolved in response to the dangers of post-partum hemorrhage. This prothrombotic state is balanced by adaptations in the fibrinolytic pathway. Activation of these systems may be more marked in the uteroplacental circulation than in the systemic circulation in both normotensive and preeclamptic pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a major pathological crisis occurs in pregnancy, such as eclampsia and preeclampsia, this delicate balance is disturbed. In addition to hypertension, there appears to be excess platelet activation, as well as endothelial damage and dysfunction, with the consequences of thrombosis, low birth weight, fetal loss, and maternal morbidity and mortality.",
"   </p>",
"   <p>",
"    The aim of this topic review is to summarize the changes in hemostasis through a normal pregnancy and puerperium and to discuss the abnormalities in coagulation and platelets during disorders of hypertension in pregnancy. The prevention, screening, and clinical manifestations of preeclampsia, including discussions of endothelial dysfunction, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=see_link\">",
"     \"Prevention of preeclampsia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHANGES IN HEMOSTASIS DURING NORMAL PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The processes involved in hemostasis include complex interactions that occur between its three main components: platelets, the endothelium, and the coagulation cascade [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/3\">",
"     3",
"    </a>",
"    ]. The fibrinolytic system has a complementary role, and is responsible for the removal of fibrin and clot dissolution. These processes interact to ensure that the circulating blood flows freely in the vascular bed and that bleeding is quickly arrested following trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In pregnancy, however, the demands made on the hemostatic and fibrinolytic systems differ markedly from the non-pregnant state. There is a marked increase in some of the coagulation factors, as well as changes in endothelial function, platelet activity, and fibrinolysis, which result in a hypercoagulable state. During delivery, placental separation presents a serious hazard of hemorrhage; adaptations are needed to combat this danger. However, as a result of these adaptations, there is also an increased risk of intravascular clotting during pregnancy, which is expressed as an increased risk of thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Coagulation and fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of the coagulation cascade results in the formation of an insoluble fibrin clot from soluble fibrinogen (",
"    <a class=\"graphic graphic_figure graphicRef69920 \" href=\"UTD.htm?31/51/32574\">",
"     figure 1",
"    </a>",
"    ). The activity of the coagulation cascade is inhibited by naturally occurring anticoagulants (eg, antithrombin, protein S, and protein C), and is balanced by the fibrinolytic system, in which fibrin and fibrinogen are degraded by plasmin, an enzyme formed from the inactive plasminogen (",
"    <a class=\"graphic graphic_figure graphicRef81428 \" href=\"UTD.htm?30/24/31118\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link&amp;anchor=H2#H2\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'The fibrinolytic system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibrinogen is the final component of the common coagulation pathway. Elevated fibrinogen levels are seen in normal pregnancy in spite of the increased plasma volume (",
"    <a class=\"graphic graphic_figure graphicRef61948 \" href=\"UTD.htm?9/32/9742\">",
"     figure 3",
"    </a>",
"    ). Indeed, the amount of fibrinogen available to the pregnant woman at delivery is often double the amount present in the non-pregnant state [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/4\">",
"     4",
"    </a>",
"    ]. There are also changes in other clotting factors, with significant increases in von Willebrand factor, factors VII, VIII, X, XII, and prothrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], which can be detected from the third month of gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link&amp;anchor=H14#H14\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\", section on 'Changes in systemic coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 100 women with uneventful pregnancies, an increase in activated factors XII and VII was noted, suggesting that both the intrinsic and extrinsic coagulation pathways were activated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/5\">",
"     5",
"    </a>",
"    ]. Further evidence that the coagulation system is activated in pregnancy is provided by the presence of increased levels of cleavage products. For example, prothrombin is cleaved by prothrombinase into thrombin and prothrombin fragments 1 and 2. The thrombin thus generated cleaves fibrinogen into fibrin monomers and fibrinopeptides A and B. Prothrombin fragments 1 and 2 and fibrinopeptides A and B are increased in normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ]. During the course of a normal pregnancy, thrombin-antithrombin [TAT] complex levels also increase significantly, providing further evidence of thrombin activation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the increases in coagulation factors and an increased ability to form thrombin, there appears to be little, if any, evidence for consistent increases in the levels of physiological anticoagulants. For example, one study noted a significant fall in the activity of proteins C and S during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/4\">",
"     4",
"    </a>",
"    ]. By contrast, a significant fall only in free protein S was seen in a second study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/6\">",
"     6",
"    </a>",
"    ], while others have found an increase in both these factors, with a concurrent fall in antithrombin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The changes seen in hemostatic factors are nevertheless accompanied by changes in the fibrinolytic pathway during normal pregnancies. For example, plasminogen and tissue-type plasminogen activator antigen levels rise [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/16\">",
"     16",
"    </a>",
"    ], resulting in an increased potential to generate plasmin, which cleaves the polymerized fibrin strand at multiple sites and releases fibrin degradation products (FDPs) (",
"    <a class=\"graphic graphic_figure graphicRef81428 \" href=\"UTD.htm?30/24/31118\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hemostasis\", section on 'Clot elimination and fibrinolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link&amp;anchor=H2#H2\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'The fibrinolytic system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alpha-2-antiplasmin levels also rise during pregnancy, partly due to a placental-derived plasminogen activator inhibitor, thus potentially limiting plasmin generation and contributing to the prothrombotic state during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/7,17-19\">",
"     7,17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Fibrin D-dimer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study of 108 normal pregnancies, a significant elevation in fibrin D-dimer, an indicator of fibrin turnover and fibrinolytic activity, was found in the second and third trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/20\">",
"     20",
"    </a>",
"    ]. This increase in fibrin D-dimer has been widely confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/10-13,21-24\">",
"     10-13,21-24",
"    </a>",
"    ]. Accordingly, the utility of a normal level of D-Dimer for helping to rule out VTE appears to fall progressively throughout the course of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link&amp;anchor=H10#H10\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\", section on 'Laboratory studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platelet count during pregnancy has been variably described as decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], or increased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/30\">",
"     30",
"    </a>",
"    ]. In a longitudinal study of changes in platelet count during normal pregnancy, the mean platelet count decreased, although there was a very wide variation, with increases in some individuals and no change in others [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link&amp;anchor=H2#H2\">",
"     \"Thrombocytopenia in pregnancy\", section on 'Normal pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link&amp;anchor=H3#H3\">",
"     \"Thrombocytopenia in pregnancy\", section on 'Gestational thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This study also reported that the mean platelet volume increased during the course of pregnancy but, again, this finding was variable, and of uncertain significance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H8#H8\">",
"     \"Automated hematology instrumentation\", section on 'Mean platelet volume'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that platelet survival time may be decreased during normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Plasma beta thromboglobulin and platelet factor 4 levels, both reflecting platelet activation, were significantly increased during normal pregnancy, indicating an increase in platelet activation, and supporting the hypothesis that there is an increased turnover of platelets during the progression of normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/33\">",
"     33",
"    </a>",
"    ]. A second study confirmed the presence of platelet activation during the progression of a normal pregnancy, but did not find differences between those with a normal pregnancy versus those with preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H27#H27\">",
"     \"Platelet function testing\", section on 'Measurement of platelet activation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Endothelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endothelium produces substances responsible for the regulation of vascular tone as well as products that influence hemostasis and platelet function. For example, prostacyclin [PGI2] is a potent vasodilator and inhibitor of platelet aggregation, whose effects are balanced by the vasoconstrictor and platelet aggregator, thromboxane. The latter is also produced by platelets, and in the uteroplacental circulation of normal pregnancy, it is believed that the production of prostacyclin is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/35\">",
"     35",
"    </a>",
"    ]. The endothelium also produces nitric oxide, another potent vasodilator, whose action is countered by the vasoconstricting hormone, endothelin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=see_link&amp;anchor=H2#H2\">",
"     \"Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)\", section on 'Vascular endothelium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology of preeclampsia likely involves both maternal and",
"    <span class=\"nowrap\">",
"     fetal/placental",
"    </span>",
"    factors. Abnormalities in the development of placental vasculature early in pregnancy may result in relative placental",
"    <span class=\"nowrap\">",
"     underperfusion/hypoxia/ischemia,",
"    </span>",
"    which then leads to release of antiangiogenic factors into the maternal circulation that alter maternal systemic endothelial function and cause hypertension and other manifestations of the disease. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a guinea pig model of pregnancy, the in vitro release of endothelium derived relaxing factor (EDRF, or nitric oxide) is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Treatment with 17-beta-estradiol increases endothelium-dependent relaxation in response to acetylcholine, a stimulator of nitric oxide synthase [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. This response was not affected by treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , an inhibitor of prostaglandin production.",
"   </p>",
"   <p>",
"    In the spontaneously hypertensive rat, an animal model of preeclampsia, pregnancy is associated with vasodilation and a profound decrease in blood pressure. This is due to nitric oxide release rather than prostacyclin production [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, nitric oxide, together with prostacyclin, plays an important role in the development and maintenance of the uteroplacental circulation as a low resistance, high flow system. It has also been suggested that reduced levels of inhibitors of the L-arginine nitric oxide pathway may play a role in the reduction of vascular tone in normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In preeclampsia and pregnancy-induced hypertension (PIH), a cross-sectional study reported that women with PIH had significantly higher levels of plasma von Willebrand factor (VWF, 19 percent), E-selectin (40 percent) and thrombomodulin (61 percent) than normotensive women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/42\">",
"     42",
"    </a>",
"    ]. Only thrombomodulin was independently associated with PIH. This molecule could be useful in monitoring and in providing clues for etiology and pathophysiology, and may have implications for the clinical complications associated with PIH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HEMOSTATIC CHANGES AFTER HYPERTENSION IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in coagulation, fibrinolysis, and platelet and vascular endothelial function are believed to play an important role in the pathogenesis of preeclampsia, which is characterized by placental hypoperfusion and infarction, fibrin deposition, consumptive thrombocytopenia, and coagulopathy (",
"    <a class=\"graphic graphic_table graphicRef72067 \" href=\"UTD.htm?27/17/27932\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnancies complicated by preeclampsia, compared with normal pregnancy, there is a significant increase in thrombin-antithrombin [TAT] complex, in vitro thrombin generation, prothrombin fragment 1+2, and fibrin D-dimer levels, whereas antithrombin and fibrinogen levels were reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Increases in TAT-complex were also found in a longitudinal study of 36 primigravida, in which four subjects subsequently developed preeclampsia and 12 patients had established preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/7\">",
"     7",
"    </a>",
"    ]. Such findings are of relevance, since TAT levels reflect the amount of thrombin formed in vivo and fibrin D-dimer levels reflect the presence of fibrinolysis.",
"   </p>",
"   <p>",
"    Accompanying this increase in coagulation in preeclampsia, there is also a reduction in physiologic anticoagulants. In two studies, no variation in the level of protein C was seen during normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/7,45\">",
"     7,45",
"    </a>",
"    ]; a reduction in protein C levels in preeclampsia was seen in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/45\">",
"     45",
"    </a>",
"    ], but not in the second [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antithrombin levels do not appear to change significantly in normal pregnancy, but may be slightly reduced in preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], while protein S levels decreased in both normal and preeclamptic pregnancies. Other investigators have reported similar reductions of antithrombin levels in preeclampsia, compared with normal pregnancy and chronic hypertension in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities in tissue factor pathway inhibitor (TFPI) have also been reported in pregnant women, including those who subsequently develop preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Other studies suggest that histidine-rich glycoprotein (HRG) and fibrinogen might be involved in the hypercoagulability and angiogenic imbalance seen in early-onset preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/50\">",
"     50",
"    </a>",
"    ]. Given that preeclampsia has been linked to angiogenic abnormalities, the presence of coagulation abnormalities could contribute to the pathophysiology of preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activity of the fibrinolytic pathway is also altered in preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/51-56\">",
"     51-56",
"    </a>",
"    ]. In a study of 42 patients with preeclampsia, significant increases in tissue-type plasminogen activator were found, while levels of urokinase-type plasminogen activator were unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two plasminogen activator inhibitors PAI-1 and PAI-2 increase progressively in normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/7,52,53\">",
"     7,52,53",
"    </a>",
"    ]; total PAI levels are found to be greater in preeclampsia than in normal pregnancies. This increase in PAI seems due to the PAI-1 fraction, as the levels of PAI-2 are decreased in pregnancies complicated by preeclampsia, particularly in those with a poor fetal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/51,54\">",
"     51,54",
"    </a>",
"    ]. However, in one study PAI-2 levels were reduced in preeclamptic patients with extensive placental infarction but not in those without infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/53\">",
"     53",
"    </a>",
"    ]. The increase in PAI-1 levels may be a reflection of endothelial damage or of platelet activation, both of which are believed to occur in preeclampsia, whereas the decrease in PAI-2 levels may reflect impaired placental function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Platelet abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most characteristic coagulation abnormalities in severe preeclampsia is a fall in the platelet count, probably due to consumption during low-grade intravascular coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition to changes in absolute platelet numbers, the platelets also appear to circulate in a more activated state (",
"    <a class=\"graphic graphic_table graphicRef72067 \" href=\"UTD.htm?27/17/27932\">",
"     table 1",
"    </a>",
"    ). One study compared platelets from 10 preeclamptic third trimester pregnant women with those from 10 normotensive third trimester pregnant women, using flow cytometry to determine platelet surface antigen expression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/55\">",
"     55",
"    </a>",
"    ]. Platelets from all the preeclamptic patients showed more extensive activation, as indicated by increased expression of P-selectin, CD63, and platelet endothelial cell adhesion molecule (PECAM)-1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H27#H27\">",
"     \"Platelet function testing\", section on 'Measurement of platelet activation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of other studies support the hypothesis of increased platelet activation in preeclampsia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a longitudinal study, increased expression of platelet CD63 during the first trimester was a predictor of the subsequent development of preeclampsia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Soluble P-selectin levels increase in preeclampsia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, levels of beta-thromboglobulin were elevated in preeclampsia, which preceded the clinical manifestation of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A cross-sectional study reported that women with pregnancy-induced hypertension had significantly raised plasma soluble P-selectin, platelet P-selectin, and beta-thromboglobulin when compared with normotensive pregnant women and controls [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/60\">",
"       60",
"      </a>",
"      ]. Using a novel adhesion assay, platelet adhesion in patients with PIH was similar to that in the normotensive pregnancies, but both were higher than the normal controls. There was no difference among the three groups with respect to platelet mass or platelet volume. Platelet P-selectin and platelet adhesion correlated significantly with gestational age and with systolic and diastolic blood pressure.",
"     </li>",
"     <li>",
"      Platelet abnormalities were also clearly evident in a comprehensive cross-sectional study in which activated platelets,",
"      <span class=\"nowrap\">",
"       platelet-monocyte/neutrophil",
"      </span>",
"      aggregates, platelet microparticles (measured by flow cytometry), and four markers of thrombin generation capacity (endogenous thrombin potential (ETP), peak height, lag time and time to peak, using the Calibrated Automated Thrombogram system) were studied, showing marked evidence of both platelet and coagulation activation in women with preeclampsia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17832/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, increased platelet activation and adhesion develop during normal pregnancy, with some indices being further altered in pregnancy-induced hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is associated with changes in endothelial function, platelets, and the coagulation cascade that confer a transient hypercoagulable state. These changes normally represent a physiologic response for controlling the hemorrhage that occurs during placental separation at delivery. However, sometimes this physiologic response progresses to a pathologic state, and results in an increased risk of thromboembolic phenomena during pregnancy.",
"   </p>",
"   <p>",
"    In addition, hypertension is a common complication of pregnancy, and in its more severe forms (eg, preeclampsia and eclampsia), abnormalities of clotting and platelet function are pathologically manifest. Widespread damage to the endothelium in preeclampsia and eclampsia results in vasoconstriction and promotes platelet adhesion and aggregation as well as the activation of coagulation factors, resulting in further hypoxic damage to the endothelium. A clearer understanding of these conditions will allow appropriate use of antithrombotic therapy, if appropriate, and enable more effective treatments to be developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26256163\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal pregnancy is associated with a transient hypercoagulable state, balanced by adaptations in the fibrinolytic pathway. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Changes in hemostasis during normal pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When eclampsia or preeclampsia occur, this balance is disturbed, along with platelet activation and endothelial damage and dysfunction (",
"      <a class=\"graphic graphic_table graphicRef72067 \" href=\"UTD.htm?27/17/27932\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hemostatic changes after hypertension in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increase in markers of coagulation along with a reduction in physiologic anticoagulants.",
"     </li>",
"     <li>",
"      The activity of the fibrinolytic pathway and endothelial function are altered, although in a complex manner.",
"     </li>",
"     <li>",
"      The platelet count is decreased along with increased platelet activation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical consequences of the hemostatic changes seen in preeclampsia and eclampsia include thrombosis, low birth weight, fetal loss, and maternal morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical implications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link&amp;anchor=H5#H5\">",
"       \"Eclampsia\", section on 'Clinical manifestations and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/1\">",
"      Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/2\">",
"      Higgins JR, Walshe JJ, Darling MR, et al. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol 1998; 179:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/3\">",
"      Szecsi PB, J&oslash;rgensen M, Klajnbard A, et al. Haemostatic reference intervals in pregnancy. Thromb Haemost 2010; 103:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/4\">",
"      Cerneca F, Ricci G, Simeone R, et al. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997; 73:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/5\">",
"      de Moerloose P, Amiral J, Vissac AM, Reber G. Longitudinal study on activated factors XII and VII levels during normal pregnancy. Br J Haematol 1998; 100:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/6\">",
"      Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol 1995; 172:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/7\">",
"      Halligan A, Bonnar J, Sheppard B, et al. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 1994; 101:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/8\">",
"      Kjellberg U, Andersson NE, Ros&eacute;n S, et al. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost 1999; 81:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/9\">",
"      Pinto S, Abbate R, Rostagno C, et al. Increased thrombin generation in normal pregnancy. Acta Eur Fertil 1988; 19:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/10\">",
"      Senent M, Bellart J, Zuazu-Jausoro I, et al. [Markers of hypercoagulability during pregnancy: thrombin-antithrombin-III complexes and D dimer]. Sangre (Barc) 1991; 36:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/11\">",
"      van Wersch JW, Ubachs JM. Blood coagulation and fibrinolysis during normal pregnancy. Eur J Clin Chem Clin Biochem 1991; 29:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/12\">",
"      Mercelina-Roumans PE, Ubachs JM, van Wersch JW. Coagulation and fibrinolysis in smoking and nonsmoking pregnant women. Br J Obstet Gynaecol 1996; 103:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/13\">",
"      Bremme K, Ostlund E, Almqvist I, et al. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992; 80:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/14\">",
"      Levine AB, Teppa J, McGough B, Cowchock FS. Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives. Contraception 1996; 53:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/15\">",
"      Uszyski M. Generation of thrombin in blood plasma of non-pregnant and pregnant women studied through concentration of thrombin-antithrombin III complexes. Eur J Obstet Gynecol Reprod Biol 1997; 75:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/16\">",
"      Bonnar J, McNicol GP, Douglas AS. Fibrinolytic enzyme system and pregnancy. Br Med J 1969; 3:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/17\">",
"      Howie PW, Prentice CR, McNicol GP. Coagulation, fibrinolysis and platelet function in pre-eclampsia, essential hypertension and placental insufficiency. J Obstet Gynaecol Br Commonw 1971; 78:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/18\">",
"      Nakashima A, Kobayashi T, Terao T. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors. Gynecol Obstet Invest 1996; 42:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/19\">",
"      Robb AO, Mills NL, Din JN, et al. Acute endothelial tissue plasminogen activator release in pregnancy. J Thromb Haemost 2009; 7:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/20\">",
"      Francalanci I, Comeglio P, Alessandrello Liotta A, et al. D-dimer plasma levels during normal pregnancy measured by specific ELISA. Int J Clin Lab Res 1997; 27:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/21\">",
"      Bellart J, Gilabert R, Fontcuberta J, et al. Fibrinolysis changes in normal pregnancy. J Perinat Med 1997; 25:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/22\">",
"      Chabloz P, Reber G, Boehlen F, et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001; 115:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/23\">",
"      Chan WS, Chunilal S, Lee A, et al. A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med 2007; 147:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/24\">",
"      Kline JA, Williams GW, Hernandez-Nino J. D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed. Clin Chem 2005; 51:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/25\">",
"      Shaper AG, Kear J, Macintosh DM, et al. The platelet count, platelet adhesiveness and aggregation and the mechanism of fibrinolytic inhibition in pregnancy and the puerperium. J Obstet Gynaecol Br Commonw 1968; 75:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/26\">",
"      Sejeny SA, Eastham RD, Baker SR. Platelet counts during normal pregnancy. J Clin Pathol 1975; 28:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/27\">",
"      Fay RA, Hughes AO, Farron NT. Platelets in pregnancy: hyperdestruction in pregnancy. Obstet Gynecol 1983; 61:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/28\">",
"      TODD ME, THOMPSON JH Jr, BOWIE EJ, OWEN CA Jr. CHANGES IN BLOOD COAGULATION DURING PREGNANCY. Mayo Clin Proc 1965; 40:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/29\">",
"      Fenton V, Saunders K, Cavill I. The platelet count in pregnancy. J Clin Pathol 1977; 30:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/30\">",
"      MOR A, YANG W, SCHWARZ A, JONES WC. Platelet counts in pregnancy and labor. A comparative study. Obstet Gynecol 1960; 16:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/31\">",
"      Sill PR, Lind T, Walker W. Platelet values during normal pregnancy. Br J Obstet Gynaecol 1985; 92:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/32\">",
"      Wallenburg HC, van Kessel PH. Platelet lifespan in normal pregnancy as determined by a nonradioisotopic technique. Br J Obstet Gynaecol 1978; 85:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/33\">",
"      Gerbasi FR, Bottoms S, Farag A, Mammen E. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol 1990; 75:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/34\">",
"      Robb AO, Din JN, Mills NL, et al. The influence of the menstrual cycle, normal pregnancy and pre-eclampsia on platelet activation. Thromb Haemost 2010; 103:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/35\">",
"      van der Weiden RM, Helmerhorst FM, Keirse MJ. Prostanoid excretion in incipient singleton and twin pregnancies. Am J Obstet Gynecol 1996; 174:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/36\">",
"      Weiner CP, Martinez E, Chestnut DH, Ghodsi A. Effect of pregnancy on uterine and carotid artery response to norepinephrine, epinephrine, and phenylephrine in vessels with documented functional endothelium. Am J Obstet Gynecol 1989; 161:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/37\">",
"      Weiner C, Martinez E, Zhu LK, et al. In vitro release of endothelium-derived relaxing factor by acetylcholine is increased during the guinea pig pregnancy. Am J Obstet Gynecol 1989; 161:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/38\">",
"      Gisclard V, Miller VM, Vanhoutte PM. Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther 1988; 244:19.",
"     </a>",
"    </li>",
"    <li>",
"     Miller VM, Aarkus LL, Vanhoutte PM. Effect of oestrogens on adrenergic and endothelium-dependent responses in the ovarian artery of the rabbit. In: Resistance Arteries, Halpern W, Pegram BL, Brayden JE, et al. (Eds), Perinatology Press, Syracuse 1988. p.136.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/40\">",
"      Ahokas RA, Mercer BM, Sibai BM. Enhanced endothelium-derived relaxing factor activity in pregnant, spontaneously hypertensive rats. Am J Obstet Gynecol 1991; 165:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/41\">",
"      Fickling SA, Williams D, Vallance P, et al. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet 1993; 342:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/42\">",
"      Nadar SK, Al Yemeni E, Blann AD, Lip GY. Thrombomodulin, von Willebrand factor and E-selectin as plasma markers of endothelial damage/dysfunction and activation in pregnancy induced hypertension. Thromb Res 2004; 113:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/43\">",
"      Schjetlein R, Haugen G, Wisl&oslash;ff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997; 76:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/44\">",
"      VanWijk MJ, Boer K, Berckmans RJ, et al. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost 2002; 88:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/45\">",
"      Gilabert J, Fernandez JA, Espa&ntilde;a F, et al. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988; 49:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/46\">",
"      Srivastava M, Bali S, Pandey J, et al. Pregnancy induced hypertension and antithrombin-III. Indian J Pathol Microbiol 1995; 38:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/47\">",
"      Paternoster DM, Stella A, Simioni P, et al. Fibronectin and antithrombin as markers of pre-eclampsia in pregnancy. Eur J Obstet Gynecol Reprod Biol 1996; 70:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/48\">",
"      Hillman S, Chant I, Gu M, et al. Tissue pathway factor inhibitor (TFPI) activity is elevated in pregnant patients at 20 weeks gestation who subsequently develop preeclampsia. Thromb Haemost 2009; 101:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/49\">",
"      Erez O, Romero R, Hoppensteadt D, et al. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med 2008; 21:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/50\">",
"      K&aring;rehed K, Wikstr&ouml;m AK, Olsson AK, et al. Fibrinogen and histidine-rich glycoprotein in early-onset preeclampsia. Acta Obstet Gynecol Scand 2010; 89:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/51\">",
"      Roes EM, Sweep CG, Thomas CM, et al. Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. Am J Obstet Gynecol 2002; 187:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/52\">",
"      Kruithof EK, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/53\">",
"      Estell&eacute;s A, Gilabert J, Aznar J, et al. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/54\">",
"      de Boer K, Lecander I, ten Cate JW, et al. Placental-type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988; 158:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/55\">",
"      Konijnenberg A, Stokkers EW, van der Post JA, et al. Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol 1997; 176:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/56\">",
"      Antovic JP, Rafik Hamad R, Antovic A, et al. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation? Thromb Haemost 2002; 88:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/57\">",
"      Konijnenberg A, van der Post JA, Mol BW, et al. Can flow cytometric detection of platelet activation early in pregnancy predict the occurrence of preeclampsia? A prospective study. Am J Obstet Gynecol 1997; 177:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/58\">",
"      Halim A, Kanayama N, el Maradny E, et al. Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Am J Obstet Gynecol 1996; 174:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/59\">",
"      Ballegeer VC, Spitz B, De Baene LA, et al. Platelet activation and vascular damage in gestational hypertension. Am J Obstet Gynecol 1992; 166:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/60\">",
"      Karalis I, Nadar SK, Al Yemeni E, et al. Platelet activation in pregnancy-induced hypertension. Thromb Res 2005; 116:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17832/abstract/61\">",
"      Macey MG, Bevan S, Alam S, et al. Platelet activation and endogenous thrombin potential in pre-eclampsia. Thromb Res 2010; 125:e76.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1317 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17832=[""].join("\n");
var outline_f17_26_17832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26256163\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHANGES IN HEMOSTASIS DURING NORMAL PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Coagulation and fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Fibrin D-dimer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Endothelium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HEMOSTATIC CHANGES AFTER HYPERTENSION IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Platelet abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26256163\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1317\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1317|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/51/32574\" title=\"figure 1\">",
"      Coagulation cascade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/24/31118\" title=\"figure 2\">",
"      Regulation of fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/32/9742\" title=\"figure 3\">",
"      Blood volume in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1317|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/17/27932\" title=\"table 1\">",
"      Hemostasis in preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=related_link\">",
"      Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_26_17833="Adjuvant systemic therapy in resectable non-small cell lung cancer";
var content_f17_26_17833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant systemic therapy in resectable non-small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17833/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17833/contributors\">",
"     Nasser Hanna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17833/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17833/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/26/17833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage I, II, or IIIA (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ) non-small cell lung cancer (NSCLC) are at substantial risk for recurrence and death even after complete surgical resection. As many as 50 percent of patients with stage IB, 70 percent of stage II, and a greater percentage of those with stage IIIA NSCLC eventually recur and die of their disease despite potentially curative surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of active platinum-based combinations and the completion of large clinical trials assessing the activity of adjuvant chemotherapy for resected NSCLC have led to the use of adjuvant chemotherapy to improve the outcome in patients with completely resected NSCLC.",
"   </p>",
"   <p>",
"    The results of the major adjuvant chemotherapy trials and their implications for the management of patients with completely resected NSCLC will be reviewed here. Other aspects of the initial treatment of patients with stages I, II, and III NSCLC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link\">",
"     \"Management of stage I and stage II non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link\">",
"     \"Management of stage III non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS AFTER RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial proportion of patients with non-small cell lung cancer (NSCLC) who undergo an apparently complete resection eventually recur. Prognostic factors are useful in determining which patients may benefit from adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathologic stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic (TNM) staging is the most important prognostic factor determining the likelihood of relapse.",
"   </p>",
"   <p>",
"    The most extensive data correlating stage with prognosis come from a series of over 31,000 cases from the Surveillance, Epidemiology and End Results (SEER) database used to validate the 7th TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/1\">",
"     1",
"    </a>",
"    ]. Survival decreased progressively with more advanced disease. For stages IA, IB, IIA, IIB, IIIA, and IIIB, the median survivals were 59, 48, 30, 24, 14, and 9 months, respectively (",
"    <a class=\"graphic graphic_figure graphicRef73088 \" href=\"UTD.htm?16/30/16871\">",
"     figure 1",
"    </a>",
"    ). These data underscore the need for effective adjuvant therapy in all stages of resected NSCLC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the TNM staging system, the detection by immunohistochemistry of single tumor cells or small clusters of cells &le;0.2 mm in greatest dimension in lymph nodes is not sufficient for reclassification as pathologically positive. Such lymph nodes are classified as negative (pN0) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the detection of such tumor cells is associated with a significantly poorer prognosis in patients with stage I NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/3\">",
"     3",
"    </a>",
"    ]. In a multicenter study that included over 1000 patients, occult nodal involvement was associated with poorer disease-free and overall survival rates compared with the absence of such occult metastases (hazard ratios 1.51, 95% CI 1.04-2.19, and 1.58, 95% CI 1.13-2.22, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Molecular markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular markers may provide additional information about the likelihood of relapse beyond that obtained from pathologic staging.",
"   </p>",
"   <p>",
"    Approaches and specific markers under study include gene expression profiling, ERCC 1 expression, abnormalities in the k-ras oncogene and p53 tumor suppressor gene, and DNA methylation markers. Additional studies will be required to determine whether these markers are useful in selecting patients for adjuvant platinum-based chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression profiles are being developed that may be useful in defining favorable and unfavorable prognostic subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Results with these gene expression profiles have the potential to divide patients with stage I disease into different risk groups, and thus identify those who might benefit from adjuvant chemotherapy.",
"   </p>",
"   <p>",
"    As an example, a 14-gene expression profile was developed in a cohort of 361 patients who had non-squamous NSCLC resected at a single institution [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/7\">",
"     7",
"    </a>",
"    ]. This profile used quantitative polymerase chain reaction (PCR) and was run on paraffin embedded tumor tissue.",
"   </p>",
"   <p>",
"    This profile was then validated in two other cohorts, one with 433 patients who had undergone resection for stage I non-squamous NSCLC and the other in 1006 patients who had undergone resection of stages I, II, or III non-squamous NSCLC. In all three cohorts, approximately 80 to 90 percent of patients had adenocarcinoma. When the original criteria were applied to the validation cohorts, the five year survival rates in the low-risk, intermediate-risk, and high-risk patients were 71, 58, and 49 percent, respectively. These differences could not be explained on the basis of other known prognostic factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     k-ras and p53",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the k-ras oncogene and the p53 tumor suppressor gene have been implicated in the pathogenesis of NSCLC.",
"   </p>",
"   <p>",
"    Abnormalities in these genes were studied in a subset of 253 patients from the JBR 10 adjuvant chemotherapy trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'JBR 10'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mutations in k-ras in their tumor did not appear to benefit from adjuvant chemotherapy, while those with wild-type k-ras did significantly better.",
"     </li>",
"     <li>",
"      Overexpression of the p53 gene as assessed by immunohistochemistry was associated with a significantly poorer prognosis compared to those who were negative for p53 overexpression, but the benefit from adjuvant chemotherapy was greater among those with p53 overexpression. Patients with mutations in p53 did not appear to benefit from adjuvant chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, in an analysis of biomarkers from 1532 patients in the LACE-bio study, patients with a mutation in k-ras codon 13 had significantly poorer outcomes when treated with adjuvant chemotherapy compared to those without a codon 13 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     DNA methylation markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methylation of the promoter region of four genes thought to be important in the pathogenesis of lung cancer (p16, CDH13, APC, and RASSF1A) has been associated with a significantly increased risk of recurrent NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/10\">",
"     10",
"    </a>",
"    ]. In a study of 167 patients who underwent potentially curative resection of stage I NSCLC, including 51 who relapsed within 40 months after surgery, the absence of promoter methylation correlated with higher rates of subsequent recurrence-free survival (77, 51, and 30 percent at five years in those with none, one or two, and three or four methylated genes, respectively).",
"   </p>",
"   <p>",
"    As with other molecular markers, these results require confirmation in a larger prospective study before they can be used to select patients for adjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant platinum-based chemotherapy is generally recommended for patients with stage II and III NSCLC following potentially curative surgery, and may also have a role in the treatment of some patients with stage IB disease (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). Adjuvant chemotherapy is not indicated for patients with resected stage IA disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Early clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 1970s and early 1980s, a number of clinical trials evaluated whether adjuvant chemotherapy improved survival following presumed complete surgical resection. These trials did not provide consistent evidence of benefit, and adjuvant chemotherapy was not widely used. Furthermore, adjuvant chemotherapy was poorly tolerated during this era, as optimal supportive measures, such as effective antiemetics, were not available.",
"   </p>",
"   <p>",
"    A 1995 meta-analysis that included data on 4357 patients from 14 randomized trials failed to demonstrate a survival advantage for adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/11\">",
"     11",
"    </a>",
"    ]. However, a subset analysis of trials using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens suggested a survival benefit, although the difference was not statistically significant.",
"   </p>",
"   <p>",
"    Key findings from this meta-analysis included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In five trials that did not contain",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , patients treated with surgery alone had a survival advantage, and the risk of death was 15 percent higher among those randomized to adjuvant chemotherapy.",
"     </li>",
"     <li>",
"      In the eight trials that utilized a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy regimen, adjuvant chemotherapy was associated with a 13 percent reduction in the risk of death, which translated into a 5 percent absolute improvement in the likelihood of surviving five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Platinum-based chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequently, multiple large trials utilized platinum-based combinations as an adjuvant following complete surgical resection of NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]. Sufficient data are now available from these trials and from a meta-analysis of these newer trials to conclude that adjuvant chemotherapy is useful for patients with completely resected NSCLC stage II and IIIA NSCLC. The data for patients with resected stage IB disease are less conclusive.",
"   </p>",
"   <p>",
"    The results of the LACE meta-analysis as well as results from the larger, homogeneous trials are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     LACE meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The improved survival with adjuvant chemotherapy using modern drug regimens was confirmed in the Lung Adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    Evaluation (LACE) meta-analysis that combined individual patient data from the five largest trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/12-16,19\">",
"     12-16,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All five trials used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy, although the IALT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/12\">",
"     12",
"    </a>",
"    ], European Big Lung [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/13\">",
"     13",
"    </a>",
"    ] and the Adjuvant Lung Project Italy (ALPI) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/14\">",
"     14",
"    </a>",
"    ] trials each integrated cisplatin into multiple chemotherapy regimens. In addition, these three trials allowed the use of adjuvant thoracic radiation at the discretion of the treating clinician, as did the ANITA trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/15\">",
"     15",
"    </a>",
"    ]. The two homogenous trials included in this meta-analysis (ANITA and JBR 10), along with IALT, the largest trial, are discussed below.",
"   </p>",
"   <p>",
"    In a pooled analysis of 4584 patients with a median follow-up of 5.2 years, adjuvant chemotherapy was associated with a decreased risk of death of 5.4 percent at five years compared to no chemotherapy (hazard ratio [HR] 0.89, 95% CI 0.82-0.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/19\">",
"     19",
"    </a>",
"    ]. The survival benefit varied according to stage and was most pronounced for patients with stage II and IIIA disease. The improvement in survival in patients with stage IB disease did not reach statistical significance, and patients with stage IA disease did worse with adjuvant chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage IA &mdash; HR 1.40 (95% CI 0.95-2.06)",
"     </li>",
"     <li>",
"      Stage IB &mdash; HR 0.93 (95% CI 0.78-1.10)",
"     </li>",
"     <li>",
"      Stage II &mdash; HR 0.83 (95% CI 0.73-0.95)",
"     </li>",
"     <li>",
"      Stage III &mdash; HR 0.83 (95% CI 0.72-0.94)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent meta-analysis that included individual patient data from these and older trials confirmed the survival benefit seen in the LACE meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/20\">",
"     20",
"    </a>",
"    ]. This meta-analysis provided additional support for the role of adjuvant chemotherapy in patients with stage IB disease. In addition, that analysis provided evidence that adjuvant chemotherapy had similar efficacy in patients whose initial treatment included both surgery and radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     ANITA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ANITA trial, 799 evaluable patients with stage IB, II, or IIIA NSCLC (36, 24, and 39 percent, respectively) were randomly assigned to four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per week) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    on day 1 every four weeks) or observation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/15\">",
"     15",
"    </a>",
"    ]. Postoperative radiation therapy (RT) was optional and determined by the centers prior to patient enrollment. RT was administered to 24 percent of chemotherapy patients and 33 percent of those assigned to observation.",
"   </p>",
"   <p>",
"    At a follow-up of 76 months, survival was significantly increased with chemotherapy (median 66 versus 44 months with observation). The absolute overall survival benefit with adjuvant chemotherapy was 8.6 percent at five years and 8.4 percent at seven years. The survival benefit appeared to be mainly in patients with stage II and IIIA disease.",
"   </p>",
"   <p>",
"    Toxicity associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    was manageable. Grade 3 or 4 neutropenia, febrile neutropenia, nausea and vomiting, constipation and peripheral neuropathy were observed in 85, 9, 27, 5, and 3 percent of patients, respectively. There were seven chemotherapy-related deaths (2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     JBR 10",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar degree of benefit for adjuvant chemotherapy was reported in the intergroup JBR 10 trial, in which 482 patients with completely resected stage IB or II (excluding T3N0) NSCLC were randomly assigned to surgery followed by four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    weekly for 16 weeks) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    days 1 and 8, every four weeks) or surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcomes from this trial were updated with a median follow-up of over nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/21\">",
"     21",
"    </a>",
"    ]. Findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The five-year overall survival rate was significantly increased with adjuvant chemotherapy compared to observation (67 versus 56 percent, hazard ratio 0.78).",
"     </li>",
"     <li>",
"      Patients with stage II disease had a significant improvement in five-year overall survival (59 versus 44 percent).",
"     </li>",
"     <li>",
"      The outcome in patients with stage I NSCLC depended upon the size of the tumor. Overall, there was no benefit (five-year survival 76 versus 69 percent, HR 1.03). In those with a primary tumor &lt;4 cm, chemotherapy was associated with a poorer outcome (73 versus 79 percent, HR 1.73), while for those with a primary tumor &gt;4 cm, chemotherapy improved survival (79 versus 59 percent, HR 0.68). These findings regarding the impact of primary tumor size are consistent with the CALGB 9633 trial. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'CALGB 9633'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There was no evidence that adjuvant chemotherapy was associated with an excess of deaths from other causes or secondary malignancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common toxicity was hematologic (grade 3 or 4 neutropenia in 73 percent of patients, febrile neutropenia in 7 percent). There were two treatment-related deaths (one each from pulmonary fibrosis and febrile neutropenia). The most frequent non-hematologic grade 3 or 4 toxicities included fatigue (15 percent), anorexia (10 percent), and vomiting (10 percent).",
"   </p>",
"   <p>",
"    The impact of adjuvant chemotherapy on quality of life (QOL) was assessed in a subset of 359 patients from this trial who completed a baseline assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients receiving adjuvant chemotherapy had transient worsening in QOL due to fatigue, nausea, and vomiting. However, the QOL of patients treated with chemotherapy returned to baseline by nine months, except for symptoms of sensory neuropathy and hearing loss.",
"   </p>",
"   <p>",
"    Similarly, an analysis of all 482 patients looking at the quality-adjusted time without symptoms or toxicity found that adjuvant chemotherapy improved quality-adjusted survival despite the toxicity associated with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of this trial in the subset of older patients are discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Elderly patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     IALT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest, platinum-based experience with adjuvant chemotherapy comes from the International Adjuvant Lung Cancer Trial (IALT), in which 1867 patients with resected stage I, II, or III NSCLC were randomly assigned to three or four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy or to observation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/12,24\">",
"     12,24",
"    </a>",
"    ]. At a median follow-up of 56 months, the five-year survival rate was higher with adjuvant chemotherapy (44.5 versus 40.4 percent, hazard ratio [HR] 0.86, 95% CI 0.76-0.98).",
"   </p>",
"   <p>",
"    At a subsequent median follow-up of 7.5 years, adjuvant chemotherapy was associated with a significant improvement in disease-free survival (HR 0.88, 95% CI 0.78-0.98) and a trend toward improved overall survival (hazard ratio [HR] 0.91, 95% CI 0.81-1.02, p=0.10) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/24\">",
"     24",
"    </a>",
"    ]. There was a trend toward an increase in non-lung cancer deaths over the entire observation period (HR 1.34, 95% CI 0.99-1.81, p=0.06).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     CALGB 9633",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer and Leukemia Group B (CALGB) 9633 is the only large adjuvant chemotherapy trial utilizing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In this trial, 344 patients with completely resected stage IB NSCLC were randomly assigned to four cycles of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    over three hours every three weeks) plus carboplatin (area under the concentration x time curve [AUC] 6 every three weeks) or observation.",
"   </p>",
"   <p>",
"    In a preliminary report presented at the American Society of Clinical Oncology (ASCO) meeting in 2004, treatment with adjuvant chemotherapy was associated with significant improvements in overall and disease-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/17\">",
"     17",
"    </a>",
"    ]. At a median follow-up of 34 months, adjuvant chemotherapy was associated with a 38 percent reduction in the risk of death (HR=0.62; 95%CI 0.41-0.95). There was a 12 percent improvement in four-year overall survival rate (71 versus 59 percent). In accordance with the statistical plan, the trial was stopped early after the planned interim analysis demonstrated a significant improvement in overall survival. Treatment was well tolerated overall, and there were no treatment-related deaths.",
"   </p>",
"   <p>",
"    However, at a median follow-up of 74 months, the difference in survival was no longer statistically significant (HR 0.83, 95% CI 0.64-1.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/18\">",
"     18",
"    </a>",
"    ]. The relatively small size of the study and its premature closure may have contributed to this outcome. The study was limited to patients with stage IB disease, a population that did not benefit in other trials. Furthermore, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , may have affected the efficacy of adjuvant chemotherapy in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Cisplatin versus carboplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The various trials on adjuvant chemotherapy have not specifically analyzed patients with stage II disease based upon the presence of multiple tumors within the same lobe of the lung (T3N0 disease). Thus, these patients are generally treated in the same manner as other patients with stage II disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data suggest that older adults with resected NSCLC should not be excluded from receiving adjuvant chemotherapy based upon age. The decision to pursue such therapy should consider both the potential benefits of such treatment and the health of the individual patient.",
"   </p>",
"   <p>",
"    The role of adjuvant chemotherapy in appropriately selected elderly patients is supported by both the LACE meta-analysis and unplanned subset analysis of the JBR 10 trial (which was one of the trials included in the meta-analysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The LACE meta-analysis also found that efficacy was not significantly different in elderly compared to younger patients, even though older patients received lower doses and fewer cycles of chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/25\">",
"       25",
"      </a>",
"      ]. In addition, no differences in severe toxicity were observed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'LACE meta-analysis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The increased difficulty in administering chemotherapy in older patients is illustrated by the subset analysis of JBR 10, in which 32 percent were more than 65 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/26\">",
"       26",
"      </a>",
"      ]. The older patients received fewer cycles of chemotherapy (median three versus four cycles in those &le;65 years). Despite this, adjuvant chemotherapy was associated with a survival benefit in those &gt;65 years that was similar to that in younger patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'JBR 10'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither of these analyses can be generalized to assess the role of adjuvant chemotherapy in the broader population of older patients, since those enrolled in these adjuvant chemotherapy trials represent a group that is probably substantially different than those of similar age who were not enrolled and may even be more fit than some of the younger patients entered into the protocol.",
"   </p>",
"   <p>",
"    Furthermore, elderly patients have not been well represented in adjuvant trials; as a result, the data are scarce and recommendations must be made on an individual basis.",
"   </p>",
"   <p>",
"    Special considerations for the use of chemotherapy in elderly patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     ASCO and NCCN guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/27\">",
"     27",
"    </a>",
"    ] and from the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/28\">",
"     28",
"    </a>",
"    ] recommend adjuvant systemic chemotherapy with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimen for patients with completely resected stage II or IIIA NSCLC.",
"   </p>",
"   <p>",
"    For patients with stage IB NSCLC, the ASCO Cancer Care Ontario guidelines do not endorse adjuvant chemotherapy for routine use because of the lack of definitive evidence establishing improved survival. The NCCN guidelines consider either observation or adjuvant chemotherapy appropriate options for patients with resected stage IB NSCLC depending on risk factors for recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13804081\">",
"    <span class=\"h2\">",
"     Choice of chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized clinical trials that compare different platinum-based chemotherapy regimens in the adjuvant setting, and the data from the LACE meta-analysis were inadequate to establish the optimal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the NCCN recommend the use of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based doublet with a third generation cytotoxic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/28\">",
"     28",
"    </a>",
"    ]. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    in combination with cisplatin should be restricted to patients with non-squamous histology. Various cisplatin chemotherapy regimens are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6370?source=see_link\">",
"     \"Treatment protocols for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1604110\">",
"    <span class=\"h1\">",
"     MOLECULARLY TARGETED AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the activity of EGFR tyrosine kinase inhibitors in patients with metastatic NSCLC that contains either a mutation in the epidermal growth factor receptor (EGFR) or the ALK fusion oncogene, there is no indication for the use of targeted agents as an adjuvant outside of a clinical trial setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients not selected based upon EGFR mutation status, adjuvant EGFR tyrosine kinase inhibitors does not improve survival. In a multicenter, placebo controlled trial, 503 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    or placebo between 2002 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients had completely resected NSCLC; adjuvant chemotherapy was permitted and patients were stratified based upon whether or not they received such treatment. In the final analysis with a minimum follow-up of four years, there was a trend toward better overall and disease-free survival in patients assigned to placebo (HR1.23, 95% CI 0.94-1.64 and HR 1.22, 95% CI 0.93-1.61, respectively). No benefit was observed in subset analyses based upon EGFR mutation status. However, these results must be interpreted with caution, since the number of patients positive for EGFR was limited.",
"   </p>",
"   <p>",
"    The potential role of adjuvant EGFR tyrosine kinase inhibitors in patients with completed resected NSCLC that contains a sensitizing mutation in EGFR remains uncertain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observational data from a single center database of 286 mutation positive patients found a trend toward improved survival in the 84 patients who received adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      (HR 0.50, 95%CI 0.23-1.08, p = 0.076) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/30\">",
"       30",
"      </a>",
"      ]. Interpretation of these results is particularly difficult since 45 percent of the patients receiving adjuvant erlotinib or gefitinib had received adjuvant cytotoxic chemotherapy as well.",
"     </li>",
"     <li>",
"      The multicenter phase II SELECT trial is studying adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      in patients with resected, state IA to IIIA EGFR mutation positive NSCLC [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/31\">",
"       31",
"      </a>",
"      ]. Preliminary results presented at the 2012 ASCO meeting indicate that this approach is feasible. The phase III RADIANT trial (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00373425?term=NCT00373425&amp;rank=1\">",
"       NCT00373425",
"      </a>",
"      ) is currently in progress; more than 1200 patients positive for EGFR by immunohistochemistry or fluorescent in situ hybridization (FISH) were randomly assigned to erlotinib or placebo. Results are pending.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NEOADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data do not support the use of neoadjuvant chemotherapy rather than immediate surgery with postoperative adjuvant chemotherapy for patients with resectable NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neoadjuvant chemotherapy has been assessed in a number of trials for patients with resectable NSCLC. A meta-analysis based upon seven trials involving 988 patients suggested that neoadjuvant chemotherapy improved overall survival when given preoperatively (five-year survival 20 versus 14 percent without neoadjuvant chemotherapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The range of results observed with neoadjuvant chemotherapy is illustrated by several contemporary phase III trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a French trial, 355 patients with NSCLC (188 with stage IB or II, 167 with stage IIIA, including 35 percent with N2 disease) were randomly assigned to surgery with or without two cycles of preoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/34\">",
"       34",
"      </a>",
"      ]. Responding patients were eligible for postoperative chemotherapy, as well. Neoadjuvant chemotherapy was associated with a trend toward a longer median disease-free survival (27 versus 13 months, p = 0.15). At a median follow-up of 14 years, the 10-year recurrence-free survival rate was significantly increased with chemotherapy plus surgery compared to surgery alone (55 versus 38 percent, HR 0.78 95% CI 0.62-0.98) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/35\">",
"       35",
"      </a>",
"      ]. There was a trend toward increased overall survival with neoadjuvant chemotherapy compared to surgery alone (29 versus 21 percent, p=0.12), and the difference was statistically significant when multivariate analysis incorporated age, T stage, and N stage (HR 0.69 95% CI 0.64-0.90).",
"     </li>",
"     <li>",
"      In the multicenter European LU22 trial, 519 patients with resectable NSCLC were randomly assigned to three cycles of platinum-based chemotherapy followed by surgery or to immediate surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/36\">",
"       36",
"      </a>",
"      ]. At randomization, 93 percent of patients had clinical stage I or II disease. The chemotherapy regimen varied at different sites; the two most widely used combinations were",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus cisplatin. Overall 75 percent of patients completed all three cycles of chemotherapy, and the objective response rate to chemotherapy was 47 percent.",
"      <br/>",
"      <br/>",
"      Despite the observed antitumor activity from chemotherapy, there was no improvement in PFS with neoadjuvant treatment (two-year PFS 53 versus 52 percent with immediate surgery; HR for recurrence 0.96, 95% CI 0.77-1.21). Similarly, there was no improvement in overall survival with preoperative chemotherapy (five-year survival 44 versus 45 percent, HR for death 1.02, 95% CI 0.80-1.31). Results were not reported as a function of stage. The negative results in this trial may be attributed to the very high percentage of patients enrolled with stage I disease. This trial also underscores the difficulties in accurately staging patients preoperatively, as 59 percent of patients on the control arm (surgery alone) had either pathological upstaging or downstaging at the time of surgery.",
"     </li>",
"     <li>",
"      In Southwest Oncology Group trial SWOG 9900, 354 patients with resectable stage IB-IIIA NSCLC were randomly assigned to three cycles of chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      followed by surgery or immediate surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/37\">",
"       37",
"      </a>",
"      ]. PFS was prolonged with neoadjuvant chemotherapy compared to immediate surgery (median 33 versus 20 months, HR 0.80 95% CI 0.619-1.04). Overall survival was also nonsignificantly longer with neoadjuvant chemotherapy (median 62 versus 41 months, HR 0.79, 95% CI 0.60-1.06). The trial was terminated prematurely when positive results were obtained in large trials using adjuvant chemotherapy.",
"     </li>",
"     <li>",
"      Neoadjuvant and adjuvant chemotherapy were compared to surgery alone in the three-armed NATCH trial [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/38\">",
"       38",
"      </a>",
"      ]. In this trial, 624 patients with IA, IB, II, or III (T3N1) NSCLC (",
"      <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"       table 1",
"      </a>",
"      ) were randomly assigned to surgery alone, neoadjuvant chemotherapy followed by surgery, or surgery followed by adjuvant chemotherapy. Chemotherapy consisted of three cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      . Compliance with chemotherapy was significantly higher with neoadjuvant rather than adjuvant chemotherapy (90 percent versus 61 percent receiving three cycles of chemotherapy). Despite this, there were no significant differences in the five-year disease-free survival rates (34, 38, and 37 percent for surgery alone, neoadjuvant chemotherapy, or adjuvant chemotherapy, respectively) or five-year overall survival rates (44, 47, and 46 percent, respectively).",
"     </li>",
"     <li>",
"      A European trial randomly assigned 270 patients to chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      followed by surgery or to surgery alone [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/39\">",
"       39",
"      </a>",
"      ]. Patients had resectable stage IB, II, or IIIA disease. Enrollment in the trial was terminated prematurely when positive results were obtained in large trials using adjuvant chemotherapy. Despite this, there were statistically significant improvements in progression-free survival (three-year rate 53 versus 48 percent, HR 0.70) and overall survival (three-year rate 68 versus 60 percent, HR 0.63).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decisions on giving neoadjuvant chemotherapy depend upon accurate clinical staging, while the decision to give adjuvant therapy is based upon the more accurate pathologic staging. Although 98 percent of patients in the NATCH trial had clinical stage I or ll disease at protocol entry, 28 percent of those who underwent immediate surgery (with or without adjuvant chemotherapy) were reclassified as pathologic stage III based upon surgical findings.",
"   </p>",
"   <p>",
"    The results of these trials and the meta-analysis do not support the use of a neoadjuvant approach rather than immediate surgery with postoperative adjuvant chemotherapy for patients with resectable NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple large randomized trials have demonstrated that adjuvant chemotherapy using modern",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens can significantly improve five-year survival in carefully selected patients with non-small cell lung cancer (NSCLC). These benefits have been confirmed in a meta-analysis of trials based upon individual patient data using modern chemotherapy regimens. The survival advantage is most pronounced for those with stage II and IIIA disease, but some patients with stage IB may benefit as well. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Platinum-based chemotherapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'LACE meta-analysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A web-based tool is available (Adjuvant! Online for lung cancer) to aid the clinician in calculating the relative risk of disease recurrence and mortality based upon clinicopathologic features and the relative benefit to be gained by adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17833/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with stage II and IIIA NSCLC who are willing and able to tolerate adjuvant chemotherapy, we recommend treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based doublet (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Platinum-based chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6370?source=see_link\">",
"       \"Treatment protocols for non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The optimal chemotherapy regimen has not been determined in randomized trials. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      should be restricted to patients with non-squamous histology. (See",
"      <a class=\"local\" href=\"#H13804081\">",
"       'Choice of chemotherapy regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      based regimens (eg, carboplatin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ) should be limited to patients with significant comorbidity and those who cannot tolerate a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based regimen. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'CALGB 9633'",
"      </a>",
"      above.)&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with stage IB NSCLC who are willing and able to tolerate adjuvant chemotherapy, we suggest adjuvant chemotherapy with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based doublet, although observation is a reasonable alternative (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The evidence from individual trials supporting the use of adjuvant therapy in patients with stage IB disease is conflicting, although the meta-analysis provides additional support for this approach. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'LACE meta-analysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Platinum-based chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with resected stage IA NSCLC, we recommend not using adjuvant chemotherapy except in the context of a clinical trial because of the favorable prognosis and absence of data supporting a benefit (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'LACE meta-analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For carefully selected older patients with resected stages IB, II, and IIIA NSCLC, we suggest adjuvant chemotherapy using the same chemotherapy regimens as for younger patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The decision of whether or not to use adjuvant chemotherapy in elderly adults must be individualized. A comprehensive geriatric analysis may be useful prior to making a decision about whether or not to proceed with adjuvant chemotherapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Elderly patients'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"       \"Comprehensive geriatric assessment for patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are no data to support the use of targeted therapy outside of a clinical trial for patients whose primary tumor contains a mutation in EGFR or the ALK fusion oncogene. (See",
"      <a class=\"local\" href=\"#H1604110\">",
"       'Molecularly targeted agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whenever possible, patients should be encouraged to participate in clinical trials.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/1\">",
"      Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2:694.",
"     </a>",
"    </li>",
"    <li>",
"     Lung. In: American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/3\">",
"      Rusch VW, Hawes D, Decker PA, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol 2011; 29:4313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/4\">",
"      Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/5\">",
"      Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007; 99:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/6\">",
"      Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007; 25:5562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/7\">",
"      Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012; 379:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/8\">",
"      Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25:5240.",
"     </a>",
"    </li>",
"    <li>",
"     Shepherd FA, Bourredjem A, Brambilla E, et al. Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. J Clin Oncol 2012; 30: (suppl; abstr 7007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/10\">",
"      Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/11\">",
"      Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/12\">",
"      Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/13\">",
"      Waller D, Gower N, Milroy MD, et AL.. The Big Lung Trial: determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting (abstract). Proc Am Soc Clin Oncol 2003; 22:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/14\">",
"      Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/15\">",
"      Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/16\">",
"      Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/17\">",
"      Strauss GM, Herndon J, Maddaus MA, et AL.. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract). Proc Am Soc Clin Oncol 2004; 23:621s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/18\">",
"      Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26:5043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/19\">",
"      Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/20\">",
"      NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/21\">",
"      Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010; 28:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/22\">",
"      Bezjak A, Lee CW, Ding K, et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 2008; 26:5052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/23\">",
"      Jang RW, Le Ma&icirc;tre A, Ding K, et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol 2009; 27:4268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/24\">",
"      Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010; 28:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/25\">",
"      Fr&uuml;h M, Rolland E, Pignon JP, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008; 26:3573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/26\">",
"      Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007; 25:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/27\">",
"      Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007; 25:5506.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/29\">",
"      Goss GD, Lorimer I, Tsao MS, et AL.. A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor, Gefitinb in Completely Resected Stage IB-IIIA Non Small Cell Lung Cancer (NSCLC), NCIC CTG BR.19. J Clin Oncol 2010; 28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/30\">",
"      D'Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012; 7:1815.",
"     </a>",
"    </li>",
"    <li>",
"     Neal JW, Pennell NA, Govindan R, et al. The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). J Clin Oncol 30, 2012 (suppl; abstr 7010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/32\">",
"      Bradbury PA, Shepherd FA. Chemotherapy and surgery for operable NSCLC. Lancet 2007; 369:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/33\">",
"      Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006; 1:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/34\">",
"      Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/35\">",
"      Westeel V, Milleron BJ, Quoix EA, et AL.. Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer. J Clin Oncol 2010; 28:515s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/36\">",
"      Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007; 369:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/37\">",
"      Pisters KM, Valli&egrave;res E, Crowley JJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 2010; 28:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/38\">",
"      Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010; 28:3138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17833/abstract/39\">",
"      Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012; 30:172.",
"     </a>",
"    </li>",
"    <li>",
"     Adjuvant! Online program available online at www.adjuvantonline.com (Accessed on November 08, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4636 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-46BEA4AD38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17833=[""].join("\n");
var outline_f17_26_17833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS AFTER RESECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathologic stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Molecular markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - k-ras and p53",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - DNA methylation markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Early clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - LACE meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - ANITA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - JBR 10",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - IALT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - CALGB 9633",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ASCO and NCCN guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13804081\">",
"      Choice of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1604110\">",
"      MOLECULARLY TARGETED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NEOADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4636|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/30/16871\" title=\"figure 1\">",
"      Nonsmall cell lung ca survival by TNM gp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4636|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=related_link\">",
"      Diagnosis and staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=related_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=related_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=related_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6370?source=related_link\">",
"      Treatment protocols for non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_26_17834="Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation";
var content_f17_26_17834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17834/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17834/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17834/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17834/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/26/17834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/26/17834/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/26/17834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cushing's disease is caused by pituitary corticotropin-(ACTH)-secreting tumors. These tumors are almost always benign and are usually microadenomas (ie, &lt;10 mm in diameter). Treatment is aimed first at the anterior pituitary gland.",
"   </p>",
"   <p>",
"    The progressive stages of treatment that may be required to cure a patient of Cushing's disease are shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef76949 \" href=\"UTD.htm?33/49/34589\">",
"     algorithm 1",
"    </a>",
"    ). Primary therapy consists of transsphenoidal surgery or pituitary irradiation. Patients who fail this first approach can be treated either by repeat transsphenoidal surgery, medical therapy, radiotherapy, or as a final resort, surgical or medical adrenalectomy. An overview of transsphenoidal surgery and pituitary irradiation for the primary therapy of Cushing&rsquo;s disease will be reviewed here. The medical therapy of Cushing&rsquo;s syndrome is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSSPHENOIDAL SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transsphenoidal microadenomectomy is currently the treatment of choice for Cushing's disease. When successful, the patient is cured and is eventually left with normal hypothalamic-pituitary-adrenal function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616841\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operative approach varies. Traditionally, the procedure involved transsphenoidal exploration through either a sublabial or endonasal approach, followed by use of a high powered microscope that allowed for binocular vision. More recently, use of an endoscope, which does not provide binocular vision, has been advocated but has not been definitively shown to be superior [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared 42 patients with Cushing's disease and a visible microadenoma on MRI who had received one or the other approach. The cure rate (76 percent) was similar in each group, but patients with the endoscopic approach had shorter hospital stays [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study using the traditional approach with microscopy reported a higher cure rate (87 percent) in 136 patients with unrevealing MRI results [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616848\">",
"    <span class=\"h2\">",
"     Extent of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of surgery varies. Ideally the entire tumor is removed while normal pituitary tissue is left behind. However, in adult patients in whom a microadenoma cannot be identified at the time of surgery and for whom fertility is not an issue, 80 to 90 percent of the pituitary should be resected, leaving a small island attached to the stalk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616855\">",
"    <span class=\"h2\">",
"     Preoperative localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, tumors are localized by the pre-operative MRI scan or by intraoperative exploration and observation by the surgeon.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to operate should not depend upon radiographic demonstration of the tumor. High-resolution, contrast-enhanced, thin-section CT scans detect only about one-third of the microadenomas, which appear hypodense after contrast injection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64273 \" href=\"UTD.htm?26/15/26866\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Because CT scans define bony structures better, the neurosurgeon may, on occasion, request them.",
"   </p>",
"   <p>",
"    Coronal projections of high-resolution MR imaging at 1.5 T with gadolinium enhancement reveal microadenomas in about 60 percent of patients and have largely replaced CT for localization (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75003 graphicRef50905 \" href=\"UTD.htm?32/12/32969\">",
"     image 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In one report, a modified technique, known as &ldquo;spoiled gradient recalled acquisition technique&rdquo; had superior sensitivity compared with conventional post-contrast spin-echo technique (80 versus 49 percent, respectively), but a higher false positive rate (4 percent versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/9\">",
"     9",
"    </a>",
"    ]. False positive MR or CT scans can be obtained in 10 percent of subjects with no endocrine disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/10\">",
"     10",
"    </a>",
"    ], who may or may not have \"non-functioning\" microadenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/11\">",
"     11",
"    </a>",
"    ]. False negative scans can occur in patients with an empty sella [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/12\">",
"     12",
"    </a>",
"    ]. Some microadenomas that cannot be visualized with preoperative MR imaging can be identified using intraoperative ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The preoperative radiographic demonstration of tumor improved the likelihood of cure in some but not all centers; other possible confounding factors such as technical experience might account for the differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective analysis of 54 patients with Cushing's disease (26 with pituitary microadenoma on preoperative MRI and 28 with a normal MRI but confirmed pituitary origin of ACTH secretion on bilateral petrosal sinus sampling), clinical outcome of transsphenoidal surgery was similar regardless of the preoperative MRI findings [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/14\">",
"       14",
"      </a>",
"      ]. Early surgical success rates were 78 and 88 percent in the normal and abnormal MRI groups, respectively, a difference that was not statistically significant.",
"     </li>",
"     <li>",
"      In a second study of 167 patients with clear-cut microadenoma on MRI, 148 of 167 (88 percent) achieved remission, suggesting that imaging localization may improve outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study, 183 of 185 (99 percent) with microadenomas on MRI had initial remission [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75084633\">",
"    <span class=\"h3\">",
"     Inferior petrosal sinus sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of ACTH gradients in the two sinuses during inferior petrosal venous sinus catheterization has been investigated as a strategy to localize the tumor (eg, predict the correct side of the pituitary tumor). However, we do not rely on this approach, based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of adults, cavernous sinus sampling or inferior petrosal sinus predicted the correct site of the tumor in 62 to 80 percent of 79 patients, depending on the symmetry of venous drainage. However, cure was achieved in only about 50 percent of 28 patients undergoing hemihypophysectomy based on this information [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of children, inferior petrosal sinus sampling correctly predicted the tumor location in only 58 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Preoperative glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative glucocorticoid replacement is not necessary unless cortisol production has been blocked by adrenal enzyme inhibitors. In this instance, the patient should be treated like a patient with adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Practice patterns are variable. Some surgeons do not administer glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/19\">",
"     19",
"    </a>",
"    ], while others give higher than normal glucocorticoid replacement intraoperatively and for one to three days postoperatively to avoid symptoms and signs of acute steroid withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/20\">",
"     20",
"    </a>",
"    ]. There have been no comparisons of the benefits of one or the other approach. One typical regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    0.5 mg every six hours for four doses only, eg, only 24 hours of glucocorticoid therapy.",
"   </p>",
"   <p>",
"    <br/>",
"    Perioperative glucocorticoid therapy entails virtually no risk for the patient, except that it must be stopped for 24 hours before serum cortisol can be measured to assess cure. Glucocorticoid replacement can be held for a few days, with careful observation for the development of adrenal insufficiency.",
"    <br/>",
"    <br/>",
"    Patients who meet the criterial for successful surgery are hypocortisolemic for up to 12 months after microadenomectomy and require glucocorticoid replacement therapy, which must be supplemented during stress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Occasional patients become anorectic and have generalized malaise and postural hypotension three or four days after surgery. These problems often respond to higher doses of glucocorticoid for several days.",
"   </p>",
"   <p>",
"    Other rare patients with long-standing severe Cushing's disease have such severe symptoms of glucocorticoid withdrawal that replacement doses of glucocorticoid are inadequate, and they temporarily require higher doses, up to twofold higher. Both clinician and patient must recognize that administration of such doses constitutes iatrogenic hypercortisolism. Every effort should be made to taper to a replacement dose, ideally within a few weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgical complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616877\">",
"    <span class=\"h3\">",
"     Diabetes insipidus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient central diabetes insipidus is common and was reported at a rate of 22 percent in a single institution with a high volume of pituitary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/21\">",
"     21",
"    </a>",
"    ]. In contrast, permanent diabetes insipidus occurs in only a few percent of patients, even among those who have subtotal resection of the gland, although, more extensive resection may increase the incidence of permanent diabetes insipidus to as much as 25 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Permanent diabetes insipidus is typically accompanied by impaired secretion of other anterior pituitary hormones, particularly thyrotropin (TSH) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/22\">",
"     22",
"    </a>",
"    ]. In a survey answered by 958 neurosurgeons, anterior pituitary insufficiency was cited as a complication of transsphenoidal hypophysectomy in 19 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyponatremia occurs in 8 to 24 percent of patients, presenting from the first to tenth post-operative day, with maximal antidiuresis at day seven [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. In one study of 52 patients without postoperative diabetes insipidus, 7 percent had symptomatic hyponatremia (plasma sodium &lt;125",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with nausea, headache,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emesis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616884\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications, apart from surgically-related morbidity, include venous thrombosis and infection, which occurred in four and one patients, respectively, of 103 studied retrospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/25\">",
"     25",
"    </a>",
"    ]. Since the risk of thromboembolic complications is increased in Cushing's syndrome, perioperative prophylaxis seems warranted in patients who are not ambulatory within a few days of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Thromboembolic events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617476\">",
"    <span class=\"h2\">",
"     Cure rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neurosurgeon experienced with transsphenoidal surgery for Cushing's patients can achieve an initial cure rate of 80 to 90 percent with microadenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/27-34\">",
"     27-34",
"    </a>",
"    ], but less than 60 percent with macroadenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/33,35\">",
"     33,35",
"    </a>",
"    ], although initial cure of 11 of 12 patients (92 percent) was reported from one center [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/36\">",
"     36",
"    </a>",
"    ]. A meta-analysis of 18 reports since 1995 showed an overall initial cure rate for micro- and macroadenomas combined of 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/37\">",
"     37",
"    </a>",
"    ]. It is important to recognize that patients who are initially &ldquo;cured&rdquo; should be considered to be in remission rather than cured, as some will recur.",
"   </p>",
"   <p>",
"    Less experienced neurosurgeons may have a cure rate as low as zero [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/38\">",
"     38",
"    </a>",
"    ]. The cure rates with microadenomas depend upon pathologic confirmation of an adenoma or unequivocal demonstration of cure after resection, since approximately one-half of these tumors cannot be imaged in advance of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other than inexperience, the reasons for failure include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All of the contents of the sella cannot be seen at surgery, so that some adenoma tissue may be missed. Diligent exploration of the entire gland is optimal if tumor is not recognized initially.",
"     </li>",
"     <li>",
"      Diffuse corticotroph hyperplasia may be present. However, this is probably extremely rare.",
"     </li>",
"     <li>",
"      The adenoma may arise in the pituitary stalk, which is not readily accessible to the surgeon. This occurred in 10 of 516 patients in one series, although all were successfully removed, with preservation of pituitary function in nine [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adenomas that arise on the surface of the gland tend to be locally invasive; tumor cells in the interstices of the dura mater or in the cavernous sinus cannot be surgically excised [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rarely, adenomas arising in ectopic sites may be the cause [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. In one series of 626 patients with Cushing's disease, five patients (0.8 percent) had parasellar tumors; a sixth patient appeared to have two distinct ACTH-secreting corticotroph adenomas, one in the periphery of the pituitary gland and the other in the cavernous sinus [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ACTH-secreting adenomas may rarely be located within the posterior lobe of the pituitary gland [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616915\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the criteria for \"cure\" after transsphenoidal surgery for Cushing&rsquo;s disease. When judged in the immediate postoperative period, patients with persistent elevations in urine cortisol are not in remission. However, the remaining patients show a spectrum of biochemical features ranging from hypoadrenalism, with undetectable serum cortisol and plasma ACTH concentrations, to apparently normal ACTH and cortisol levels.",
"   </p>",
"   <p>",
"    When judged by long-term outcome, patients with a postoperative serum cortisol less than 50",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    have the highest long-term remission rates, 85 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. As noted, initial cure rates of up to 80 to 90 percent after transsphenoidal microadenectomy, based on postoperative serum cortisol concentrations &lt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (138",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    within 14 days of surgery, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/27,29,38,49,50\">",
"     27,29,38,49,50",
"    </a>",
"    ]. In two studies, long-term remission rates were 65 and 80 percent in patients judged by this less stringent post-operative criterion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625572\">",
"    <span class=\"h4\">",
"     Factors affecting postoperative cortisol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors influence the immediate post-operative cortisol value:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal corticotropes of patients with mild or intermittent hypercortisolism may not be suppressed sufficiently to cause hypocortisolism after complete tumor resection. Normal cortisol dynamics in these patients reflect normal function and not residual tumor. This can be inferred by documentation of a normal diurnal cortisol pattern as opposed to relatively invariant pattern in patients with persistent Cushing&rsquo;s disease.",
"     </li>",
"     <li>",
"      Plasma ACTH concentration, and therefore the serum cortisol concentration, depend upon the number of adenomatous corticotrophs remaining immediately after surgery. The number may be too low to stimulate detectable cortisol secretion, either basally or in response to stimulation, but may be sufficient to survive, slowly multiply, and eventually reconstitute a large enough adenoma to cause recurrent Cushing&rsquo;s syndrome. In addition, rare patients have diffuse or multicentric disease [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postoperative glucocorticoid administration has been postulated to inhibit ACTH secretion from remaining tumor cells and thus possibly lead to a falsely reassuring suppressed cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75084746\">",
"    <span class=\"h4\">",
"     Late remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients appear to have a late remission, and early postoperative assessment of serum cortisol concentration is not sufficient to predict outcome, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients show a gradual decline in cortisol during the first three months after surgery, possibly indicating progressive necrosis of remaining tumor cells. This was illustrated in a study of 17 patients whose serum cortisol remained higher than 50",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mcg/dL)",
"      </span>",
"      within the first 14 days after surgery. However, serum cortisols had decreased to &lt;50",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mcg/dL)",
"      </span>",
"      by three months after surgery and all remained in remission during one to eight years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, 5.6 percent of 620 patients had late remission, occurring at 38",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      50 days, suggesting that decisions about additional therapy should await additional testing in patients with persistent hypercortisolism after transsphenoidal surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar surgical cure rates have been observed in children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/32,54,55\">",
"     32,54,55",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 42 children, remission occurred in 35 (83 percent), 26 of whom were carefully followed for a mean of 7.2 years. Seven subsequently relapsed after an average of 4.2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/55\">",
"       55",
"      </a>",
"      ]. Overall, pituitary surgery performed once or twice resulted in a long-term remission in about 80 percent of children.",
"     </li>",
"     <li>",
"      In another series of 72 children, 70 achieved initial and 66 (94 percent) achieved long-term remission during follow-up of 24 to 120 months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Macroadenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients with macroadenomas have lower cure rates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, of 137 patients with microadenomas operated on at a single center, 123 (90 percent) were cured initially. Of those, seven (6 percent) had a recurrence during a mean follow-up period of six years (range 1 to 11 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/33\">",
"       33",
"      </a>",
"      ]. Seventeen patients had macroadenomas, of whom 11 (65 percent) were cured initially; 3 of the 11 (27 percent) later had a recurrence.",
"     </li>",
"     <li>",
"      In another study, initial remission was reported in five of eight patients with macroadenomas extending beyond the sella (63 percent), and in 43 of 52 with intrasellar macroadenomas (83 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/57\">",
"       57",
"      </a>",
"      ]. Both of these studies defined surgical cure as a postoperative serum cortisol &lt;5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (138",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      In contrast, the cure rate (after surgery alone) in a series of 18 macroadenomas was only 12.5 percent when the more stringent criterion described above was used (serum cortisol &lt;1.8",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      [50",
"      <span class=\"nowrap\">",
"       nmol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H618116\">",
"    <span class=\"h3\">",
"     Biochemical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of criteria have been used to assess cure after transsphenoidal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/59\">",
"     59",
"    </a>",
"    ]. We currently suggest the following approach to assessing patient outcome.",
"   </p>",
"   <p>",
"    Serum cortisol should be measured at 8 AM at least 24 hours after the last physiologic dose of glucocorticoid, beginning three to seven days after surgery, to assess cure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/60\">",
"     60",
"    </a>",
"    ]. Ideally, measurements are obtained for three consecutive days without glucocorticoid therapy.",
"   </p>",
"   <p>",
"    The best criteria of cure are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An undetectable serum cortisol concentration",
"     </li>",
"     <li>",
"      An undetectable plasma ACTH concentration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although an extremely low serum cortisol concentration (&lt;1.8",
"    <span class=\"nowrap\">",
"     mcg/dL,",
"    </span>",
"    50",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    is the best predictor of cure, some patients with low but detectable serum cortisol concentrations (2 to 4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [55 to 110",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    that suppress with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may remain in remission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/60\">",
"     60",
"    </a>",
"    ], as may those with cortisol values &lt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (138",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    However, a persistently detectable serum cortisol concentration, even though it represents a major decrease from the preoperative concentration and is well within the normal range, may represent incomplete resection and an increased risk of recurrence. In these patients, measurement of cortisol every one to two weeks for up to three months may reveal a decline to less than 50",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients without a fully suppressed postoperative cortisol concentration may require some glucocorticoid replacement; ideally this is 10 mg or less of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    daily in the morning to avoid suppression of corticotropes. The blood sample is obtained before the morning hydrocortisone dose is taken. If the serum cortisol concentration becomes undetectable, the patient is considered cured.",
"   </p>",
"   <p>",
"    Measurement of 24-hour urinary cortisol excretion may be useful since it confirms the serum cortisol concentration. The urine collection should begin at least 24 hours after the last small dose (10 mg or less) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ; a small maintenance dose (0.25 to 0.5 mg) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may be substituted before and during the collection. Excretion of less than &lt;10",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (28",
"    <span class=\"nowrap\">",
"     nmol/day)",
"    </span>",
"    is consistent with cure.",
"   </p>",
"   <p>",
"    Management of patients with intermediate postoperative values of serum or plasma cortisol should be individualized. If there is a reason to suspect that tumor tissue was left behind and that the normal values reflect tumor ACTH secretion, measurement of salivary cortisol at midnight can be helpful, as it is likely to be abnormal with persistent disease. Lack of cortisol suppression to the overnight 1 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test may help confirm the suspicion of persistent disease. In these cases, additional therapy may be recommended. Patients with normal cortisol dynamics, in whom the normal corticotropes may not be suppressed, may be followed.",
"   </p>",
"   <p>",
"    ACTH, corticotropin-releasing hormone (CRH), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    stimulation tests are not helpful in these patients because it is not clear how to interpret the results in this setting. A persistent response of cortisol and ACTH to the administration of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (10 mcg) may suggest a higher risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36312?source=see_link&amp;anchor=H9#H9\">",
"     \"Vasopressin and desmopressin stimulation test\", section on 'Evaluating for cure of Cushing's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true long-term cure rate is not known with certainty in part because of differing criteria for cure, and also because of inadequate follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/47,48,50-52,54,64-67\">",
"     47,48,50-52,54,64-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average reported interval to recurrence is about 40 months. However, this figure is in part an artifact of the relatively short duration of follow-up of many patients. One study prospectively analyzed the recurrence rate in 79 cured patients by survival analysis; 19 percent had recurrences by five years, and the cumulative recurrence rate was 26 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/67\">",
"     67",
"    </a>",
"    ]. Others have reported a similar recurrence rate of 22 percent in 45 patients at a mean follow-up of nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a similar time to recurrence in children; the average interval in seven children was 4.2 years (nine months to 6.2 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of recurrence can be predicted only in part by postoperative serum cortisol measurements. As an example, a recurrence rate as high as 12 percent was reported in patients with undetectable postoperative cortisol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/48\">",
"     48",
"    </a>",
"    ]. Complete normalization of adrenocortical function may be a better predictor of outcome. As an example, in one study of patients after transsphenoidal surgery, those who had low post-surgery serum cortisol concentrations and subsequent recovery of normal circadian rhythm and responsiveness to insulin-induced hypoglycemia had much lower recurrence rates (3.4 percent) than those who did not recover normal hypothalamic-pituitary-adrenal function (50 to 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other hormone tests also provide prognostic information. In one report, for example, the recurrence rate increased from 11 percent in patients who had postoperative urinary cortisol values of 20",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (56",
"    <span class=\"nowrap\">",
"     nmol/day)",
"    </span>",
"    or less to 36 percent when the value was above 35",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (96",
"    <span class=\"nowrap\">",
"     nmol/day;",
"    </span>",
"    normal range 20 to 48",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [55 to 331",
"    <span class=\"nowrap\">",
"     nmol/day]).",
"    </span>",
"    Similarly, the recurrence rate increased from 8 percent in patients with a plasma ACTH concentration of 20",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (4.4",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    or less to 53 percent in those with a plasma ACTH concentration of 35",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (7.7",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    or more (normal range up 100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [22",
"    <span class=\"nowrap\">",
"     pmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Long-term monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be reevaluated annually for several years and less frequently thereafter. This is particularly true in those who had initial intermittent hypersecretion of cortisol; these patients may seem to be cured after surgery but continue to secrete excess cortisol intermittently [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/68\">",
"     68",
"    </a>",
"    ]. Reevaluation should include measurements of late night salivary cortisol, a 24-hour urinary cortisol,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the 1 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/65\">",
"     65",
"    </a>",
"    ], using the same criteria as for diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    .) Patients should be encouraged to consider re-evaluation at any time if they experience a return of their initial symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment if surgery fails",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with clear persistent disease after surgery (elevated urine cortisol excretion), one must first review the pathology results. If a tumor is not present on pathology, it is prudent to review the results of the tests for the differential diagnosis. In one study, 5 of 52 patients who failed surgery were found to have ectopic ACTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/31\">",
"     31",
"    </a>",
"    ]. In patients with equivocal results, additional testing may be needed.",
"   </p>",
"   <p>",
"    Five therapeutic options remain in patients who are not cured in whom the diagnosis of Cushing&rsquo;s disease appears to be correct:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeat resection of residual corticotroph adenoma, particularly if residual tumor is visible on MRI. Reoperation has a lower success rate than initial surgery. In three studies, 57 to 71 percent of patients who underwent early reoperation had evidence of biochemical cure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/49,69,70\">",
"       49,69,70",
"      </a>",
"      ]. However, many of them developed other pituitary hormone deficiencies as a result of the second procedure. In one study, immediate reoperation was most successful when the pathology indicates incomplete resection.",
"     </li>",
"     <li>",
"      Irradiation of the pituitary gland (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Pituitary irradiation'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Medical therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Adrenalectomy: medical or surgical.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Medical adrenalectomy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      , for example, may be used in conjunction with pituitary irradiation (",
"      <a class=\"graphic graphic_algorithm graphicRef76949 \" href=\"UTD.htm?33/49/34589\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link&amp;anchor=H6330785#H6330785\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Mitotane'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical adrenalectomy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19496?source=see_link&amp;anchor=H362181869#H362181869\">",
"       \"Persistent or recurrent Cushing&rsquo;s disease: Surgical adrenalectomy\", section on 'Surgical adrenalectomy'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice for therapy is individualized. For example, a young woman desiring fertility might choose to have adrenalectomy or repeat transsphenoidal exploration to avoid hypogonadism associated with radiotherapy and the teratogenicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    . A patient with extreme hypercortisolism might choose adrenalectomy to achieve rapid control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PITUITARY IRRADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pituitary irradiation is the rational choice when pituitary surgery is either not the initial therapy or has failed. In addition, it may be considered as the initial therapy in children because it is as successful as transsphenoidal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/55,71,72\">",
"     55,71,72",
"    </a>",
"    ]. Patients with hypercortisolism should receive adrenal enzyme inhibitors (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ) to achieve eucortisolism until the radiation therapy is successful [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=see_link\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To judge the effectiveness of radiation therapy, steroidogenesis inhibitor(s) can be stopped for a few days and 24-hour urine cortisol measured. Patients should receive teaching about adrenal insufficiency symptoms and should be instructed to return to the clinician if they experience such symptoms.",
"   </p>",
"   <p>",
"    A total of 42 to 45 Gy (4200 to 4500 rad) of conventional megavoltage radiation is delivered to the pituitary gland at a rate of 1.8 to 2",
"    <span class=\"nowrap\">",
"     Gy/day",
"    </span>",
"    (180 to 200",
"    <span class=\"nowrap\">",
"     rad/day),",
"    </span>",
"    usually via multiple collimated ports using a linear accelerator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pituitary radiation is a noninvasive procedure that has few adverse effects. It also appears to decrease the incidence of Nelson's syndrome (enlarging, locally invasive pituitary corticotroph tumors causing hyperpigmentation) in patients who are not cured and must eventually undergo medical or surgical adrenalectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19496?source=see_link\">",
"     \"Persistent or recurrent Cushing&rsquo;s disease: Surgical adrenalectomy\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617067\">",
"    <span class=\"h3\">",
"     Primary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of pituitary radiation as primary treatment can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Approximately 80 percent of children are cured [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The cure rate in adults is 15 to 53 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/1,75\">",
"       1,75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Another 25 to 30 percent of adults are sufficiently improved that they require no additional therapy or only small doses of an adrenal enzyme inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the almost immediate reduction in ACTH and cortisol secretion after successful pituitary surgery, the maximal benefits of pituitary radiation do not occur for at least 9 to 12 months and occasionally as long as 18 to 24 months. Occasional \"improved\" patients may be cured several years after treatment. Children usually respond more rapidly, often within three months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617074\">",
"    <span class=\"h3\">",
"     Secondary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The percent of patients responding to radiation therapy may be somewhat higher after failed transsphenoidal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, one study evaluated the efficacy of somewhat higher doses of radiation (48 to 54 Gy, mean 50 Gy) in 30 adults with persistent or recurrent Cushing's disease after unsuccessful transsphenoidal surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/76\">",
"       76",
"      </a>",
"      ]. The remission rate increased progressively with time from 20 percent at six months to 43 percent at 12 months to 83 percent at 60 months. None of the 25 patients who were cured had a relapse of Cushing's disease after remission was achieved.",
"     </li>",
"     <li>",
"      In another study of 40 patients, 32 achieved remission at a follow-up interval of nine years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious side effects are rare in either adults or children with the treatment schedule described above given as primary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/1,79\">",
"     1,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less than 5 percent of the patients developed clinical growth hormone or thyrotropin deficiency, sometimes years after radiation.",
"     </li>",
"     <li>",
"      With provocative testing, some degree of pituitary deficiency has been detected in a majority of patients who receive two to three times the currently recommended fractional dose [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypopituitarism was more frequent in the reports described above in patients with failed transsphenoidal surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/76,78\">",
"       76,78",
"      </a>",
"      ]. In these studies, 43 to 57 percent of the patients had growth hormone deficiency, and about 33 percent had deficiencies of one or more other pituitary hormones. In one study of children, five of six who received both transsphenoidal surgery and radiation developed growth hormone deficiency, which was transient in two [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a long-standing controversy regarding a possible increased risk of death from cerebrovascular disease after radiation therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A long-term follow-up study of 342 patients with pituitary tumors (mostly non-secreting tumors) treated by surgery and radiation suggested that radiation per se is not responsible for these deaths. The characteristics of radiation were not different in the cerebrovascular deaths (31 patients), compared with a control group that received radiation but did not have a cerebrovascular event [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/82\">",
"       82",
"      </a>",
"      ]. Patients with Cushing's disease (and acromegaly) were excluded from this study because of the increased incidence of cerebrovascular complications in these patients irrespective of the mode of therapy.",
"     </li>",
"     <li>",
"      In a second study, 33 of 334 patients with pituitary adenoma died of cerebrovascular disease after radiation therapy, representing an increased relative risk of 4.11 compared to national age, sex, and interval mortality rates [",
"      <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher cure rates can be attained by delivering up to 110 Gy (11,000 rad) of alpha-particle or proton beam external radiation over a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/84,85\">",
"     84,85",
"    </a>",
"    ] or 198Au or 90Y interstitial radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. These regimens, however, are associated with a higher incidence of side effects, especially hypopituitarism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic radiosurgery with the 60Co gamma knife or the linear accelerator photon knife is another treatment option [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. These instruments can deliver over 100 Gy (10,000 rad) of radiation with great precision in one treatment session (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64369 graphicRef76201 \" href=\"UTD.htm?7/52/8008\">",
"     image 3A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    In one series, 89 patients aged 5 to 67 with ACTH-producing tumors were treated with stereotactic radiosurgery and 18 were followed for 12 to 22 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/90\">",
"     90",
"    </a>",
"    ]. Of the 89 patients, 64 received one, and 25 had two or more courses of treatment. There were no treatment-related deaths, and vision and visual fields were not affected. Urinary cortisol levels gradually normalized in 83 percent, and no tumor recurrences were noted. Radiation-induced endocrine deficiencies developed in two-thirds of treated patients, some as late as 10 years after treatment.",
"   </p>",
"   <p>",
"    In a second study of gamma knife after failed transsphenoidal surgery, 49 of 90 patients (54 percent) were cured, as indicated by normal urine cortisol excretion, on average about one year after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/91\">",
"     91",
"    </a>",
"    ]. Ten patients (20 percent) had subsequent recurrence of hypercortisolism within five years and 20 (22 percent) developed new hormonal deficiencies. Five patients developed new visual deficits or third, fourth, or sixth cranial nerve deficits; two of these patients had undergone prior conventional fractionated radiation therapy, and four of them had received previous gamma knife therapy.",
"   </p>",
"   <p>",
"    Other studies have shown that when side effects do arise with stereotactic radiation, they may occur within two years of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/92\">",
"     92",
"    </a>",
"    ], although the median time is five years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stereotactic radiosurgery is more convenient for patients, as it requires only one or two treatments, but it is generally more expensive than conventional radiation therapy (in the United States). There are not sufficient data to know if the side-effect profile differs between the two.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RESOLUTION OF CUSHING'S STIGMATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are cured of Cushing's disease or whose hypercortisolism is controlled, signs and symptoms of hypercortisolism improve rapidly and disappear over a period of 2 to 12 months. Thinning of the skin improves within weeks; muscle strength improves more slowly. Central obesity is usually lost, whereas patients with generalized obesity, especially if sustained for years rather than months, usually have difficulty losing the additional weight. Hypertension and glucose intolerance improve but may not be cured.",
"   </p>",
"   <p>",
"    Unlike other forms of osteoporosis, the osteoporosis of Cushing's syndrome improves rapidly during the first two years after cure and more gradually thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/94\">",
"     94",
"    </a>",
"    ]. Unfortunately, vertebral compression fractures and aseptic necrosis of the proximal humerus and femur cause permanent deformity and are a major incentive for early cure of Cushing's syndrome.",
"   </p>",
"   <p>",
"    Five years after cure, 15 patients in one study had a higher prevalence of atherosclerosis and increased cardiovascular risk factors, probably due to residual abdominal obesity and insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/77\">",
"     77",
"    </a>",
"    ]. Similar findings were reported in a study of 41 patients who had a higher prevalence of obesity and dyslipidemia than case controls at a mean follow-up duration of 11 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/26/17834/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resolution of neuropsychiatric symptoms after surgery is variable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Neuropsychological changes and cognition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31367?source=see_link\">",
"     \"Glucocorticoid effects on the nervous system and behavior\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=see_link\">",
"       \"Patient information: Cushing's syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=see_link\">",
"       \"Patient information: Cushing's syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=see_link\">",
"       \"Patient information: Cushing's syndrome treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616954\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cushing's disease is caused by pituitary corticotropin-(ACTH)-secreting tumors. These tumors are almost always benign and are usually microadenomas (ie, &lt;10 mm in diameter). Treatment is aimed first at the anterior pituitary gland.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most adult patients with Cushing&rsquo;s disease, we suggest transsphenoidal surgery with an experienced surgeon as primary therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transsphenoidal surgery'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The operative approach varies. Traditionally, the procedure involved transsphenoidal exploration through either a sublabial or endonasal approach, followed by use of a high powered microscope that allowed for binocular vision. More recently, use of an endoscope, which does not provide binocular vision, has been advocated.",
"      <br/>",
"      <br/>",
"      The extent of surgery varies. Ideally, the entire tumor is removed while normal pituitary tissue is left behind. However, in adult patients in whom a microadenoma cannot be identified at the time of surgery and for whom fertility is not an issue, 80 to 90 percent of the pituitary should be resected, leaving a small island attached to the stalk.",
"      <br/>",
"      <br/>",
"      MRI is performed preoperatively to try and locate the pituitary tumor. However, surgery should be performed even if a tumor is not visualized.",
"     </li>",
"     <li>",
"      Surgical complications &ndash; the main surgical complication is diabetes insipidus, which occurs transiently in up to about 20 percent of patients, but is rarely permanent. (See",
"      <a class=\"local\" href=\"#H616877\">",
"       'Diabetes insipidus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biochemical assessment for cure: (see",
"      <a class=\"local\" href=\"#H618116\">",
"       'Biochemical criteria'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Long-term monitoring: (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Long-term monitoring'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Management if surgery fails: (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment if surgery fails'",
"      </a>",
"      above). First, the presence of tumor on pathology and the previous testing should be examined to ensure that the diagnosis is correct. If only a part of the tumor has been resected, immediate repeat surgery is an option.",
"     </li>",
"     <li>",
"      For patients with a secure diagnosis in whom surgery has failed and with little or no radiologically-detectable residual tumor, we suggest radiation therapy as the next step (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients with mild disease in whom the possibility of an additional two to four months of hypercortisolism is not deemed too risky, medical therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      is an alternative, recognizing that it is successful in only a minority of individuals. Radiation with adjunctive medical therapy may be best in those with dural invasion or who have unresectable remaining tumor. Adrenalectomy may be favored in those with severe hypercortisolism who need immediate cure or in women desiring pregnancy in whom steroidogenesis inhibitors are contraindicated.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/1\">",
"      Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/2\">",
"      Porterfield JR, Thompson GB, Young WF Jr, et al. Surgery for Cushing's syndrome: an historical review and recent ten-year experience. World J Surg 2008; 32:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/3\">",
"      Atkinson AB, Kennedy A, Wiggam MI, et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005; 63:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/4\">",
"      Watson JC, Shawker TH, Nieman LK, et al. Localization of pituitary adenomas by using intraoperative ultrasound in patients with Cushing's disease and no demonstrable pituitary tumor on magnetic resonance imaging. J Neurosurg 1998; 89:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/5\">",
"      Marcovitz S, Wee R, Chan J, Hardy J. The diagnostic accuracy of preoperative CT scanning in the evaluation of pituitary ACTH-secreting adenomas. AJR Am J Roentgenol 1987; 149:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/6\">",
"      Saris SC, Patronas NJ, Doppman JL, et al. Cushing syndrome: pituitary CT scanning. Radiology 1987; 162:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/7\">",
"      Escourolle H, Abecassis JP, Bertagna X, et al. Comparison of computerized tomography and magnetic resonance imaging for the examination of the pituitary gland in patients with Cushing's disease. Clin Endocrinol (Oxf) 1993; 39:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/8\">",
"      Dwyer AJ, Frank JA, Doppman JL, et al. Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging. Radiology 1987; 163:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/9\">",
"      Patronas N, Bulakbasi N, Stratakis CA, et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab 2003; 88:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/10\">",
"      Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/11\">",
"      Parent AD, Bebin J, Smith RR. Incidental pituitary adenomas. J Neurosurg 1981; 54:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/12\">",
"      Lipkin EW, Fujimoto WY. Cushing's syndrome in a patient with suppressible hypercortisolism and an empty sella. West J Med 1984; 140:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/13\">",
"      Ram Z, Shawker TH, Bradford MH, et al. Intraoperative ultrasound-directed resection of pituitary tumors. J Neurosurg 1995; 83:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/14\">",
"      Salenave S, Gatta B, Pecheur S, et al. Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropin-secreting microadenomas. J Clin Endocrinol Metab 2004; 89:3371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/15\">",
"      Prevedello DM, Pouratian N, Sherman J, et al. Management of Cushing's disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg 2008; 109:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/16\">",
"      Jagannathan J, Smith R, DeVroom HL, et al. Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg 2009; 111:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/17\">",
"      Liu C, Lo JC, Dowd CF, et al. Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2004; 61:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/18\">",
"      Batista D, Gennari M, Riar J, et al. An assessment of petrosal sinus sampling for localization of pituitary microadenomas in children with Cushing disease. J Clin Endocrinol Metab 2006; 91:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/19\">",
"      Patil CG, Veeravagu A, Prevedello DM, et al. Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery 2008; 63:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/20\">",
"      Olson BR, Rubino D, Gumowski J, Oldfield EH. Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab 1995; 80:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/21\">",
"      Nemergut EC, Zuo Z, Jane JA Jr, Laws ER Jr. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg 2005; 103:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/22\">",
"      Burke CW, Adams CB, Esiri MM, et al. Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome? Clin Endocrinol (Oxf) 1990; 33:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/23\">",
"      Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/24\">",
"      Hensen J, Henig A, Fahlbusch R, et al. Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. Clin Endocrinol (Oxf) 1999; 50:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/25\">",
"      Semple PL, Laws ER Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. J Neurosurg 1999; 91:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/26\">",
"      Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:3662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/27\">",
"      Salassa RM, Laws ER Jr, Carpenter PC, Northcutt RC. Transsphenoidal removal of pituitary microadenoma in Cushing's disease. Mayo Clin Proc 1978; 53:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/28\">",
"      Bigos ST, Somma M, Rasio E, et al. Cushing's disease: management by transsphenoidal pituitary microsurgery. J Clin Endocrinol Metab 1980; 50:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/29\">",
"      Carpenter PC. Cushing's syndrome: update of diagnosis and management. Mayo Clin Proc 1986; 61:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/30\">",
"      Chandler WF, Schteingart DE, Lloyd RV, et al. Surgical treatment of Cushing's disease. J Neurosurg 1987; 66:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/31\">",
"      Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 1988; 109:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/32\">",
"      Styne DM, Grumbach MM, Kaplan SL, et al. Treatment of Cushing's disease in childhood and adolescence by transsphenoidal microadenomectomy. N Engl J Med 1984; 310:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/33\">",
"      Swearingen B, Biller BM, Barker FG 2nd, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 1999; 130:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/34\">",
"      Shimon I, Ram Z, Cohen ZR, Hadani M. Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 2002; 51:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/35\">",
"      Aron DC, Findling JW, Fitzgerald PA, et al. Cushing's syndrome: problems in management. Endocr Rev 1982; 3:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/36\">",
"      Fomekong E, Maiter D, Grandin C, Raftopoulos C. Outcome of transsphenoidal surgery for Cushing's disease: a high remission rate in ACTH-secreting macroadenomas. Clin Neurol Neurosurg 2009; 111:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/37\">",
"      Kelly DF. Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's Syndrome. Neurosurg Focus 2007; 23:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/38\">",
"      Burch W. A survey of results with transsphenoidal surgery in Cushing's disease. N Engl J Med 1983; 308:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/39\">",
"      Bakiri F, Tatai S, Aouali R, et al. Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up. J Endocrinol Invest 1996; 19:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/40\">",
"      Mason RB, Nieman LK, Doppman JL, Oldfield EH. Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. J Neurosurg 1997; 87:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/41\">",
"      Meij BP, Lopes MB, Ellegala DB, et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 2002; 96:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/42\">",
"      Kammer H, George R. Cushing's disease in a patient with an ectopic pituitary adenoma. JAMA 1981; 246:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/43\">",
"      Wilson CB, Mindermann T, Tyrrell JB. Extrasellar, intracavernous sinus adrenocorticotropin-releasing adenoma causing Cushing's disease. J Clin Endocrinol Metab 1995; 80:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/44\">",
"      Pluta RM, Nieman L, Doppman JL, et al. Extrapituitary parasellar microadenoma in Cushing's disease. J Clin Endocrinol Metab 1999; 84:2912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/45\">",
"      Weil RJ, Vortmeyer AO, Nieman LK, et al. Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing's disease. J Clin Endocrinol Metab 2006; 91:2656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/46\">",
"      Estrada J, Garc&iacute;a-Ur&iacute;a J, Lamas C, et al. The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2001; 86:5695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/47\">",
"      Newell-Price J. Transsphenoidal surgery for Cushing's disease: defining cure and following outcome. Clin Endocrinol (Oxf) 2002; 56:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/48\">",
"      Yap LB, Turner HE, Adams CB, Wass JA. Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf) 2002; 56:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/49\">",
"      Ram Z, Nieman LK, Cutler GB Jr, et al. Early repeat surgery for persistent Cushing's disease. J Neurosurg 1994; 80:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/50\">",
"      Esposito F, Dusick JR, Cohan P, et al. Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2006; 91:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/51\">",
"      Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 1995; 80:3114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/52\">",
"      Pereira AM, van Aken MO, van Dulken H, et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab 2003; 88:5858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/53\">",
"      Valassi E, Biller BM, Swearingen B, et al. Delayed remission after transsphenoidal surgery in patients with Cushing's disease. J Clin Endocrinol Metab 2010; 95:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/54\">",
"      Leinung MC, Kane LA, Scheithauer BW, et al. Long term follow-up of transsphenoidal surgery for the treatment of Cushing's disease in childhood. J Clin Endocrinol Metab 1995; 80:2475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/55\">",
"      Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997; 82:3196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/56\">",
"      Batista DL, Oldfield EH, Keil MF, Stratakis CA. Postoperative testing to predict recurrent Cushing disease in children. J Clin Endocrinol Metab 2009; 94:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/57\">",
"      Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 2004; 89:6348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/58\">",
"      Woo YS, Isidori AM, Wat WZ, et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005; 90:4963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/59\">",
"      Orth DN. Cushing's syndrome. N Engl J Med 1995; 332:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/60\">",
"      McCance DR, Besser M, Atkinson AB. Assessment of cure after transsphenoidal surgery for Cushing's disease. Clin Endocrinol (Oxf) 1996; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/61\">",
"      Colombo P, Dall'Asta C, Barbetta L, et al. Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease. Eur J Endocrinol 2000; 143:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/62\">",
"      Romanholi DJ, Machado MC, Pereira CC, et al. Role for postoperative cortisol response to desmopressin in predicting the risk for recurrent Cushing's disease. Clin Endocrinol (Oxf) 2008; 69:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/63\">",
"      Losa M, Mortini P, Dylgjeri S, et al. Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease. Clin Endocrinol (Oxf) 2001; 55:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/64\">",
"      Guilhaume B, Bertagna X, Thomsen M, et al. Transsphenoidal pituitary surgery for the treatment of Cushing's disease: results in 64 patients and long term follow-up studies. J Clin Endocrinol Metab 1988; 66:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/65\">",
"      Tahir AH, Sheeler LR. Recurrent Cushing's disease after transsphenoidal surgery. Arch Intern Med 1992; 152:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/66\">",
"      Jeffcoate WJ, Dauncey S, Selby C. Restoration of dexamethasone suppression by incomplete adenomectomy in Cushing's disease. Clin Endocrinol (Oxf) 1985; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/67\">",
"      Sonino N, Zielezny M, Fava GA, et al. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1996; 81:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/68\">",
"      Streeten DH, Anderson GH Jr, Dalakos T, Joachimpillai AD. Intermittent hypercortisolism: a disorder strikingly prevalent after hypophysial surgical procedures. Endocr Pract 1997; 3:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/69\">",
"      Benveniste RJ, King WA, Walsh J, et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 2005; 102:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/70\">",
"      Locatelli M, Vance ML, Laws ER. Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2005; 90:5478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/71\">",
"      Jennings AS, Liddle GW, Orth DN. Results of treating childhood Cushing's disease with pituitary irradiation. N Engl J Med 1977; 297:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/72\">",
"      Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986; 58:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/73\">",
"      SALASSA RM, KEARNS TP, KERNOHAN JW, et al. Pituitary tumors in patients with Cushing's syndrome. J Clin Endocrinol Metab 1959; 19:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/74\">",
"      NELSON DH, MEAKIN JW, THORN GW. ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. Ann Intern Med 1960; 52:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/75\">",
"      Lamberts SW, de Jong FH, Birkenh&auml;ger JC. Evaluation of a therapeutic regimen in Cushing's disease. The predictability of the result of unilateral adrenalectomy followed by external pituitary irradiation. Acta Endocrinol (Copenh) 1977; 86:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/76\">",
"      Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997; 336:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/77\">",
"      Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/78\">",
"      Minniti G, Osti M, Jaffrain-Rea ML, et al. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol 2007; 84:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/79\">",
"      Howlett TA, Plowman PN, Wass JA, et al. Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up. Clin Endocrinol (Oxf) 1989; 31:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/80\">",
"      Sharpe GF, Kendall-Taylor P, Prescott RW, et al. Pituitary function following megavoltage therapy for Cushing's disease: long term follow up. Clin Endocrinol (Oxf) 1985; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/81\">",
"      Dias RP, Kumaran A, Chan LF, et al. Diagnosis, management and therapeutic outcome in prepubertal Cushing's disease. Eur J Endocrinol 2010; 162:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/82\">",
"      Erfurth EM, B&uuml;low B, Svahn-Tapper G, et al. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 2002; 87:4892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/83\">",
"      Brada M, Ashley S, Ford D, et al. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) 2002; 57:713.",
"     </a>",
"    </li>",
"    <li>",
"     Heavy ion therapy: Alpha particle therapy of pituitary tumors. In: Recent advances in diagnosis and treatment of pituitary tumors, Linfoot, JA (Eds), Raven Press, New York 1979. p.245.",
"    </li>",
"    <li>",
"     Kjellberg RN, Kliman B, Swisher B, et al.. Proton beam therapy of Cushing's disease and Nelson's syndrome. In: Secretory tumors of the pituitary gland, Black PML, et al. (Eds), Raven Press, New York 1984. p.295.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/86\">",
"      Burke CW, Doyle FH, Joplin GF, et al. Cushing's disease. Treatment by pituitary implantation of radioactive gold or yttrium seeds. Q J Med 1973; 42:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/87\">",
"      Cassar J, Doyle FH, Mashiter K, Joplin GF. Treatment of Cushing's disease in juveniles with interstitial pituitary irradiation. Clin Endocrinol (Oxf) 1979; 11:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/88\">",
"      Lunsford LD, Flickinger J, Lindner G, Maitz A. Stereotactic radiosurgery of the brain using the first United States 201 cobalt-60 source gamma knife. Neurosurgery 1989; 24:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/89\">",
"      Friedman WA, Bova FJ. The University of Florida radiosurgery system. Surg Neurol 1989; 32:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/90\">",
"      H&ouml;ybye C, Grenb&auml;ck E, R&auml;hn T, et al. Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 2001; 49:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/91\">",
"      Jagannathan J, Sheehan JP, Pouratian N, et al. Gamma Knife surgery for Cushing's disease. J Neurosurg 2007; 106:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/92\">",
"      Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/93\">",
"      Samaan NA, Schultz PN, Yang KP, et al. Endocrine complications after radiotherapy for tumors of the head and neck. J Lab Clin Med 1987; 109:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/94\">",
"      Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995; 80:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/26/17834/abstract/95\">",
"      Barahona MJ, Resmini E, Sucunza N, Webb SM. Diagnosis of cure in Cushing's syndrome: lessons from long-term follow-up. Front Horm Res 2010; 38:152.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 118 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17834=[""].join("\n");
var outline_f17_26_17834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H616954\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSSPHENOIDAL SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H616841\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H616848\">",
"      Extent of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H616855\">",
"      Preoperative localization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75084633\">",
"      - Inferior petrosal sinus sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Preoperative glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgical complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H616877\">",
"      - Diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H616884\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H617476\">",
"      Cure rates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H616915\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H625572\">",
"      Factors affecting postoperative cortisol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H75084746\">",
"      Late remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Macroadenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H618116\">",
"      - Biochemical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Long-term monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment if surgery fails",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PITUITARY IRRADIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H617067\">",
"      - Primary therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H617074\">",
"      - Secondary therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RESOLUTION OF CUSHING'S STIGMATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H616954\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/118|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?33/49/34589\" title=\"algorithm 1\">",
"      Treatment Cushings disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/118|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/15/26866\" title=\"diagnostic image 1\">",
"      Cushings disease CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/55/38772\" title=\"diagnostic image 2A\">",
"      Cushings disease MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/46/39653\" title=\"diagnostic image 2B\">",
"      Cushings disease MRI II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/38/1635\" title=\"diagnostic image 3A\">",
"      Stereotactic radiosurgery I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/51/3891\" title=\"diagnostic image 3B\">",
"      Stereotactic radiosurgery II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31367?source=related_link\">",
"      Glucocorticoid effects on the nervous system and behavior",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3081?source=related_link\">",
"      Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=related_link\">",
"      Patient information: Cushing's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=related_link\">",
"      Patient information: Cushing's syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/47/10994?source=related_link\">",
"      Patient information: Cushing's syndrome treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19496?source=related_link\">",
"      Persistent or recurrent Cushing&rsquo;s disease: Surgical adrenalectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36312?source=related_link\">",
"      Vasopressin and desmopressin stimulation test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_26_17835="Criteria for outpatient liver biopsy";
var content_f17_26_17835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for outpatient liver biopsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The patient must be able to return to the hospital in which",
"the procedure was performed within 30 minutes of any adverse symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        The patient must have reliable persons stay with him or her during the first night after the biopsy to provide care and transportation, if necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        The patient",
"should have no complications or associated serious medical problems",
"that increase the risk of the biopsy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        The facility",
"in which the biopsy is performed should have approved laboratory, blood",
"banking unit, easy access to an inpatient bed, and personnel to monitor",
"the patient for at least six hours* after the biopsy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        The patient",
"should be hospitalized after the biopsy if there is evidence of",
"bleeding, bile leak, pneumothorax, or other organ puncture, or if",
"post-biopsy pain requires more than one dose of analgesics in the first",
"four hours after biopsy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Many centers currently monitor patients for only&nbsp;three to&nbsp;four hours.",
"    </div>",
"    <div class=\"reference\">",
"     From: Jacobs WH, Goldberg SB. Dig Dis Sci 1989; 34:322.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17835=[""].join("\n");
var outline_f17_26_17835=null;
var title_f17_26_17836="Pericardial involvement in connective tissue and other diseases";
var content_f17_26_17836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated frequency and type of pericardial involvement in connective tissue diseases, granulomatous diseases, and autoinflammatory diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Systemic disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated frequency of pericardial involvement (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of pericardial involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Connective tissue diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic lupus erythematosus",
"       </td>",
"       <td>",
"        &gt;50",
"       </td>",
"       <td>",
"        Pericardial effusion, pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatoid arthritis",
"       </td>",
"       <td>",
"        10-30",
"       </td>",
"       <td>",
"        Pericardial effusion (30 percent), pericarditis (10 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic sclerosis",
"       </td>",
"       <td>",
"        Symptomatic (&lt;20), overall (&gt;60)",
"       </td>",
"       <td>",
"        Pericardial effusion, pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polymyositis and dermatomyositis",
"       </td>",
"       <td>",
"        &lt;10",
"       </td>",
"       <td>",
"        Pericarditis, pericardial effusion, cardiac tamponade (case reports)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed connective tissue disease",
"       </td>",
"       <td>",
"        10-30",
"       </td>",
"       <td>",
"        Pericarditis, pericardial effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sjogren syndrome",
"       </td>",
"       <td>",
"        &lt;30",
"       </td>",
"       <td>",
"        Pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Behcet's disease",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Granulomatous diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Pericardial effusion, pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Autoinflammatory diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Familial Mediterranean Fever (FMF)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TNF receptor-1 associated periodic syndrome (TRAPS)",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Pericarditis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17836=[""].join("\n");
var outline_f17_26_17836=null;
var title_f17_26_17837="Rapid overview of rapid sequence intubation in children";
var content_f17_26_17837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview of rapid sequence intubation in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preoxygenation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Begin preoxygenation as soon as the decision to intubate is considered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer oxygen at the highest concentration available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify conditions that will affect choice of medications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify conditions that will predict difficult intubation or bag-mask ventilation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assemble equipment and check for function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop contingency plan for failed intubation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pretreatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atropine: All children &le;1 year, children &lt;5 years receiving succinycholine, and older children receiving a second dose of succinylcholine. Dose: 0.02 mg/kg IV (maximum single dose 0.5 mg, minimum 0.1 mg; if no IV access, can be given IM).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine: Optional for increased intracranial pressure. Dose: 1.5 mg/kg IV (maximum dose 100 mg). Give 2 to 3 minutes before intubation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etomidate: Safe with hemodynamic instability, neuroprotective, transient adrenal corticosuppression. Do",
"        <strong>",
"         not",
"        </strong>",
"        use routinely in patients with septic shock. Dose: 0.3 mg/kg IV.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketamine: Safe with hemodynamic instability if patient is not catecholamine depleted. Use in patients with bronchospasm and septic shock. Use with caution in patients with increased intracranial pressure. Dose: 1 to 2 mg/kg IV. (If no IV access, can be given IM dose: 3 to 7 mg/kg).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midazolam: Time to clinical effect is longer, inconsistently induces unconsciousness. May cause hemodynamic instability at doses required for sedation. Dose: 0.2 to 0.3 mg/kg IV (maximum dose 2 mg, onset of effect requires 2 to 3 minutes).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiopental: Neuroprotective. Do not use with hemodynamic instability. Dose: 3 to 5 mg/kg IV.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Paralytic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Succinycholine: Do not use with chronic myopathy or denervating neuromuscular disease; 48 to 72 hours after burn, crush, or denervating injury; malignant hyperthermia; or pre-exisiting hyperkalemia. Dose: infants and young children: 2 mg/kg IV, older children: 1 to 1.5 mg/kg IV. (If IV access unobtainable, can be given IM, dose: 3 to 5 mg/kg).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rocuronium: Use for children with contraindication for succinylcholine. Suggested dose: 1 mg/kg IV (range 0.6 to 1.2 mg/kg).",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Protection and positioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintain manual cervical spine immobilization during intubation in the trauma patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If cervical spine injury is not potentially present, put the patient in the \"sniffing position\" (ie, head forward so that the external auditory canal is anterior to the shoulder and the nose and mouth point to the ceiling). Apply cricoid pressure when the child is unconscious. Remove cricoid pressure if it causes airway obstruction or difficulty viewing the larynx.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If used, maintain cricoid pressure until tracheal tube position is verified.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Positioning, with placement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confirm tracheal tube placement with end-tidal CO2 detection and auscultation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Postintubation management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiograph for tracheal tube placement; provide ongoing sedation (eg, midazolam), analgesia (eg, fentanyl 1 mcg per kilogram), and, if indicated, paralysis.",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    If IV access unobtainable, intraosseous administration of drugs listed is feasible (no data for ketamine).",
"    <div class=\"footnotes\">",
"     * Not available in the United States and Canada.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Vecuronium may be used in children with contraindications to succinylcholine and when rocuronium is not available. Suggested dose for RSI: 0.15 to 0.2 mg/kg. Patients may experience prolonged and unpredictable duration of paralysis at this dose.",
"     <br/>",
"     &Delta; If decompensation after successful intubation use DOPE mnemonic to find cause:",
"     <br/>",
"     - D: Dislodgement of the tube (right mainstem or esophageal)",
"     <br/>",
"     - O: Obstruction of tube",
"     <br/>",
"     - P: Pneumothorax",
"     <br/>",
"     - E: Equipment failure (ventilator malfunction, oxygen disconnected or not on).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17837=[""].join("\n");
var outline_f17_26_17837=null;
var title_f17_26_17838="HRT invasive breast CA WHI";
var content_f17_26_17838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    HRT increases invasive breast cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 576px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Women's Health Initiative, combined estrogen-progestin replacement therapy (red) was associated with a significant increase in invasive breast cancer (HR 1.24, unadjusted 95 percent CI 1.01 to 1.54) when compared with placebo (green).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Chlebowski, RT, Hendrix, SL, Langer, RD, et al. Risks and benefits of estrogen and progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2003; 289:3243.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17838=[""].join("\n");
var outline_f17_26_17838=null;
var title_f17_26_17839="Patellar reduction technique";
var content_f17_26_17839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Reduction of patellar dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The knee is held in mild flexion. The distal thigh is fixed in place by an assistant. While slowly extending the knee, slight pressure is applied to the lateral aspect of the patella to reposition it medially.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_26_17839=[""].join("\n");
var outline_f17_26_17839=null;
